var title_f12_31_12784="Endoscopic image of a transampullary plastic stent";
var content_f12_31_12784=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F50266&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F50266&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Endoscopic image of a transampullary plastic stent",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 298px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Endoscopic image of a transampullary straight (Amsterdam) plastic stent.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Douglas G. Adler, MD, FACG, FASGE.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_31_12784=[""].join("\n");
var outline_f12_31_12784=null;
var title_f12_31_12785="Upper papillae in VKC";
var content_f12_31_12785=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F76654&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F76654&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Upper tarsal signs in vernal keratoconjunctivitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 397px; height: 256px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    With vernal keratoconjunctivitis (VKC), the upper papillae may assume a \"cobblestone\" appearance. Visualization of these changes requires everting the upper lids.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_31_12785=[""].join("\n");
var outline_f12_31_12785=null;
var title_f12_31_12786="FAST perisplenic left flank probe position";
var content_f12_31_12786=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F73731&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F73731&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    FAST: Perisplenic (left flank) probe position",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 334px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This image shows proper probe position for obtaining a view of the&nbsp;splenorenal interface.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Manoj Pariyadath, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_31_12786=[""].join("\n");
var outline_f12_31_12786=null;
var title_f12_31_12787="Patient information: Mitral stenosis in adults (The Basics)";
var content_f12_31_12787=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/85373\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?35/42/36516\">",
"         Chambers and valves of the heart",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_figure\" href=\"UTD.htm?33/35/34354\">",
"          Transthoracic echocardiogram (echo)",
"         </a>",
"         <li>",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/63/7154\">",
"           Person having an ECG",
"          </a>",
"         </li>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?20/32/20994\">",
"         Patient information: Atrial fibrillation (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?21/43/22195\">",
"         Patient information: Coughing up blood (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?24/51/25395\">",
"         Patient information: ECG and stress test (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?24/13/24787\">",
"         Patient information: Echocardiogram (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?17/12/17601\">",
"         Patient information: Heart failure (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?35/42/36514\">",
"         Patient information: Heart murmurs (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?11/23/11635\">",
"         Patient information: Prosthetic valves (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?38/61/39889\">",
"         Patient information: Pulmonary hypertension in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?6/46/6883\">",
"         Patient information: Shortness of breath (dyspnea) (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?0/16/261\">",
"         Patient information: Atrial fibrillation (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?33/5/33877\">",
"         Patient information: Heart failure (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Mitral stenosis in adults (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/mitral-stenosis-in-adults-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H204599195\">",
"      <span class=\"h1\">",
"       What is mitral stenosis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Mitral stenosis is a condition in which 1 of the valves in the heart, called the mitral valve, doesn&rsquo;t open fully. When they work normally, the heart valves:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Open all the way to let blood flow through them",
"       </li>",
"       <li>",
"        Keep blood flowing in only 1 direction",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      The mitral valve keeps blood flowing from the left atrium to the left ventricle (",
"      <a class=\"graphic graphic_figure graphicRef58389 \" href=\"UTD.htm?35/42/36516\">",
"       figure 1",
"      </a>",
"      ). In mitral stenosis, the mitral valve does not open fully so the valve opening is too narrow. Then blood can get backed up in the blood vessels in the lungs and in the right side of the heart.",
"     </p>",
"     <p>",
"      When the valve opening is very narrow, the blood flow from the left atrium to the left ventricle might be less than normal. Doctors call it &ldquo;heart failure&rdquo; when blood gets backed up in the lungs and right side of the heart, and not enough blood flows forward.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H204599210\">",
"      <span class=\"h1\">",
"       What are the symptoms of mitral stenosis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Early on, most people have no symptoms. They might find out they have mitral stenosis after their doctor or nurse hears a heart murmur on a routine exam. A heart murmur is an extra sound in the heartbeat that doctors or nurses hear when they listen to the heart with a stethoscope.",
"     </p>",
"     <p>",
"      When people have symptoms, they have symptoms of heart failure. These can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Trouble breathing &ndash; This is the most common symptom. At first, people usually have trouble breathing only during physical activity. But later on, people can have trouble breathing at rest, too.",
"       </li>",
"       <li>",
"        Feeling tired",
"       </li>",
"       <li>",
"        A severe cough, or coughing up blood or mucus",
"       </li>",
"       <li>",
"        Swelling in the legs",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Mitral stenosis can also lead to problems such as:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        A heart rhythm problem called &ldquo;atrial fibrillation&rdquo;",
"       </li>",
"       <li>",
"        Blood clots forming in the heart &ndash; If blood clots form in the heart, pieces can break off and travel through the blood vessels to other parts of the body. They can then get stuck in and block off small blood vessels. This can cause organ damage and symptoms.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H204599225\">",
"      <span class=\"h1\">",
"       Is there a test for mitral stenosis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. The test done most often to check for mitral stenosis is an echocardiogram (also called an &ldquo;echo&rdquo;). This test uses sound waves to create a picture of the heart as it beats. It shows the size of the heart chambers, how well the heart is pumping, and how well the heart valves are working (",
"      <a class=\"graphic graphic_figure graphicRef77971 \" href=\"UTD.htm?33/35/34354\">",
"       figure 2",
"      </a>",
"      ).",
"     </p>",
"     <p>",
"      Sometimes, people have a test called a &ldquo;stress test&rdquo; along with their echo. A stress test measures how well the heart works when it pumps very fast. When a stress test is done with an echo, it&rsquo;s called a &ldquo;stress echo.&rdquo;",
"     </p>",
"     <p>",
"      All people with mitral stenosis will have a test called an electrocardiogram (also called an &ldquo;ECG&rdquo; or &ldquo;EKG&rdquo;). This test measures the electrical activity in the heart (",
"      <a class=\"graphic graphic_figure graphicRef53145 \" href=\"UTD.htm?6/63/7154\">",
"       figure 3",
"      </a>",
"      ).",
"     </p>",
"     <p>",
"      Some people with mitral stenosis will also have a chest X-ray. A chest X-ray shows the size and shape of the heart. It can also show changes in the lungs from mitral stenosis or other diseases.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H204599240\">",
"      <span class=\"h1\">",
"       How is mitral stenosis treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Treatment depends on your symptoms and how severe your mitral stenosis is. If you have mild mitral stenosis or no symptoms, you might not need any treatment. But your doctor will follow you to see if your mitral stenosis gets worse or you start to have symptoms.",
"     </p>",
"     <p>",
"      If your mitral stenosis causes symptoms or is severe, treatment can include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        A procedure to open your mitral valve &ndash; For this procedure, a doctor inflates a balloon in the narrowed mitral valve to try to open it.",
"       </li>",
"       <li>",
"        Surgery &ndash; Doctors can do different types of surgery to treat mitral stenosis. One type involves opening up the narrowed mitral valve. Another type involves replacing the narrowed valve with a new valve. This new valve can be made from metal or from valve tissue from a pig, cow, or horse. In some cases, a new valve comes from another person.",
"       </li>",
"       <li>",
"        Medicines &ndash; A procedure or surgery is the main way to treat mitral stenosis that causes symptoms. But certain medicines can help with symptoms or prevent problems caused by the mitral stenosis.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H204599255\">",
"      <span class=\"h1\">",
"       Can I play sports?",
"      </span>",
"      &nbsp;&mdash;&nbsp;It depends on your mitral stenosis and symptoms. You and your doctor should discuss the level of physical activity that is right for you.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H204599270\">",
"      <span class=\"h1\">",
"       Do I need to take antibiotics before I go to the dentist?",
"      </span>",
"      &nbsp;&mdash;&nbsp;No. In the past, doctors recommended that people with mitral stenosis take antibiotics before going to the dentist or having certain medical or dental procedures. But now, only people with certain heart conditions need antibiotics before going to the dentist or having a procedure. Most people with mitral stenosis do not need antibiotics for those times.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H204599285\">",
"      <span class=\"h1\">",
"       What if I want to get pregnant?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you want to get pregnant, talk with your doctor before you start trying. Pregnancy can worsen symptoms of mitral stenosis. Because of this, your doctor might recommend treating your mitral stenosis before you get pregnant.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H204599300\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/42/36514?source=see_link\">",
"       Patient information: Heart murmurs (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/13/24787?source=see_link\">",
"       Patient information: Echocardiogram (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/51/25395?source=see_link\">",
"       Patient information: ECG and stress test (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?11/23/11635?source=see_link\">",
"       Patient information: Prosthetic valves (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?20/32/20994?source=see_link\">",
"       Patient information: Atrial fibrillation (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?21/43/22195?source=see_link\">",
"       Patient information: Coughing up blood (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?38/61/39889?source=see_link\">",
"       Patient information: Pulmonary hypertension in adults (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?17/12/17601?source=see_link\">",
"       Patient information: Heart failure (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?6/46/6883?source=see_link\">",
"       Patient information: Shortness of breath (dyspnea) (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?33/5/33877?source=see_link\">",
"       Patient information: Heart failure (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?0/16/261?source=see_link\">",
"       Patient information: Atrial fibrillation (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?12/31/12787?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 85373 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.234.146.186-6167F63EEA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_31_12787=[""].join("\n");
var outline_f12_31_12787=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H204599195\">",
"      What is mitral stenosis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H204599210\">",
"      What are the symptoms of mitral stenosis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H204599225\">",
"      Is there a test for mitral stenosis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H204599240\">",
"      How is mitral stenosis treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H204599255\">",
"      Can I play sports?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H204599270\">",
"      Do I need to take antibiotics before I go to the dentist?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H204599285\">",
"      What if I want to get pregnant?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H204599300\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/85373\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?35/42/36516\">",
"      Chambers and valves of the heart",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_figure\" href=\"UTD.htm?33/35/34354\">",
"       Transthoracic echocardiogram (echo)",
"      </a>",
"      <li>",
"       <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/63/7154\">",
"        Person having an ECG",
"       </a>",
"      </li>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?0/16/261?source=related_link\">",
"      Patient information: Atrial fibrillation (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?20/32/20994?source=related_link\">",
"      Patient information: Atrial fibrillation (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?21/43/22195?source=related_link\">",
"      Patient information: Coughing up blood (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/51/25395?source=related_link\">",
"      Patient information: ECG and stress test (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/13/24787?source=related_link\">",
"      Patient information: Echocardiogram (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?33/5/33877?source=related_link\">",
"      Patient information: Heart failure (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?17/12/17601?source=related_link\">",
"      Patient information: Heart failure (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/42/36514?source=related_link\">",
"      Patient information: Heart murmurs (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/23/11635?source=related_link\">",
"      Patient information: Prosthetic valves (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?38/61/39889?source=related_link\">",
"      Patient information: Pulmonary hypertension in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?6/46/6883?source=related_link\">",
"      Patient information: Shortness of breath (dyspnea) (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_31_12788="Lymphocutaneous sporotrichosis arm";
var content_f12_31_12788=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F50115&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F50115&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Lymphocutaneous sporotrichosis on upper limb with ulcerative fungating lesions typically spreading upward",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 334px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: da Rosa AC, Scroferneker ML, Vettorato R, et al. Epidemiology of sporotrichosis: a study of 304 cases in Brazil. J Am Acad Dermatol 2005; 52:451. Copyright &copy; 2005 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_31_12788=[""].join("\n");
var outline_f12_31_12788=null;
var title_f12_31_12789="Enhancing patient adherence to asthma therapy";
var content_f12_31_12789=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"14\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Enhancing patient adherence to asthma therapy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/31/12789/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/31/12789/contributors\">",
"     William Bailey, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/31/12789/contributors\">",
"     Andrea J Apter, MD, MSc, MA",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/31/12789/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/31/12789/contributors\">",
"     Bruce S Bochner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/31/12789/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/31/12789/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/31/12789/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patient adherence to medical regimens is a major problem in chronic disease management. Adherence to asthma medication regimens tends to be very poor, with the reported rates of nonadherence ranging from 30 to 70 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?12/31/12789/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Up to three quarters of the total costs associated with asthma may be due to poor asthma control. Improved patient adherence may lead to improvements in asthma control and quality of life [",
"    <a class=\"abstract\" href=\"UTD.htm?12/31/12789/abstract/4\">",
"     4",
"    </a>",
"    ]. The role of the clinician is to adequately inform the patient about the prescribed regimen, and to discuss the importance of adherence even in the absence of symptoms. In the patient who subsequently manifests nonadherence, the clinician should explore with the patient barriers to adherence and methods to overcome these barriers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     REASONS FOR NONADHERENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of factors are associated with nonadherence to asthma therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/31/12789/abstract/1,2,5\">",
"     1,2,5",
"    </a>",
"    ]. Medication-related factors include difficulties with inhaler devices, complex regimens, side effects, cost of medication, dislike of medication, and distant pharmacies.",
"   </p>",
"   <p>",
"    Factors unrelated to medications include misunderstanding or lack of instruction, fears about side effects, dissatisfaction with health care professionals,",
"    <span class=\"nowrap\">",
"     unexpressed/undiscussed",
"    </span>",
"    fears or concerns, inappropriate expectations, poor",
"    <span class=\"nowrap\">",
"     supervision/training",
"    </span>",
"    or follow up, anger about one's condition or its treatment, underestimation of severity, cultural issues, stigmatization, forgetfulness or complacency, attitudes toward ill health, and religious issues [",
"    <a class=\"abstract\" href=\"UTD.htm?12/31/12789/abstract/6\">",
"     6",
"    </a>",
"    ]. Social barriers such as complicated work schedules, caring for other family members, or even the perceived safety of the neighborhood can all affect adherence [",
"    <a class=\"abstract\" href=\"UTD.htm?12/31/12789/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several other reasons make adherence to asthma treatment recommendations problematic: medication regimens are of long duration and include multiple medicines; dosing may occur on both a fixed schedule and an as needed basis; and patients go through periods of symptom remission [",
"    <a class=\"abstract\" href=\"UTD.htm?12/31/12789/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A number of types of nonadherence can interfere with therapy, including underuse, overuse, or erratic use [",
"    <a class=\"abstract\" href=\"UTD.htm?12/31/12789/abstract/1,8\">",
"     1,8",
"    </a>",
"    ]. Underuse of asthma medications appears to be more common than overuse [",
"    <a class=\"abstract\" href=\"UTD.htm?12/31/12789/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. In a study comparing self-reported use of inhaled medications recorded in a diary to actual use determined by an electronic monitor of inhaler activation, it was found that subjects were not as compliant as they reported to be in their diaries [",
"    <a class=\"abstract\" href=\"UTD.htm?12/31/12789/abstract/11\">",
"     11",
"    </a>",
"    ]. Another study found that inhaled beta agonists are no more likely to be overused than anti-inflammatory agents [",
"    <a class=\"abstract\" href=\"UTD.htm?12/31/12789/abstract/12\">",
"     12",
"    </a>",
"    ]. This observation tends to dispel the concern that patients will overuse inhaled beta agonists because of their fast symptom relief.",
"   </p>",
"   <p>",
"    It is important to appreciate that nonadherence does not always represent irrational behavior. There are many influences that may make a patient-initiated change in the regimen appropriate, such as a belief that the medication is not needed, intolerable side effects, and problems with cost. This problem has been described as \"intelligent nonadherence\" [",
"    <a class=\"abstract\" href=\"UTD.htm?12/31/12789/abstract/13\">",
"     13",
"    </a>",
"    ]. Interventions such as shared decision-making or problem-solving that take into account the beliefs and priorities of each patient have had some, but not complete success, with shared decision-making being most successful [",
"    <a class=\"abstract\" href=\"UTD.htm?12/31/12789/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     IMPROVING ADHERENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The National Asthma Education and Prevention Program (NAEPP) Guidelines for the Diagnosis and Management of Asthma provide a number of suggestions to enhance adherence [",
"    <a class=\"abstract\" href=\"UTD.htm?12/31/12789/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One of the first, and most important, steps is to establish the goals of therapy with the patient. Inform the patient of the general goals of asthma therapy and determine the patient's goals as well. With the patient, come to an agreement on what the goals of therapy should be [",
"    <a class=\"abstract\" href=\"UTD.htm?12/31/12789/abstract/15,17\">",
"     15,17",
"    </a>",
"    ]. The clinician should explain the recommended actions and the benefits that come from these actions. If possible, incorporate the patient's goals or expectations into the list of benefits. For example, \"Using medicine before the start of the game will allow you to stay in for the entire period\". At the end of this discussion, ask the patient to verbally (or, in some cases, in writing) express agreement to take the recommended actions. Below are a number of steps the clinician can take to clarify the regimen and enhance adherence [",
"    <a class=\"abstract\" href=\"UTD.htm?12/31/12789/abstract/2,16\">",
"     2,16",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Identify factors that make the patient not adhere to the regimen",
"     </li>",
"     <li>",
"      Clarify the patient's expectations for treatment and address fears or concerns",
"     </li>",
"     <li>",
"      Involve the patient and the family in development of the treatment plan",
"     </li>",
"     <li>",
"      Simplify the regimen as much as possible",
"     </li>",
"     <li>",
"      Explain how each medication works to control or prevent symptoms",
"     </li>",
"     <li>",
"      Test patients' understanding by having them repeat instructions to you in their own words, or provide a scenario and ask patients how they would respond",
"     </li>",
"     <li>",
"      Determine if a patient can afford the prescribed medications",
"     </li>",
"     <li>",
"      Provide positive reinforcement",
"     </li>",
"     <li>",
"      Discuss a patient's adherence to their medication plan during follow-up consultations",
"     </li>",
"     <li>",
"      Encourage the patient to seek support through a family member, caregiver, friend, neighbor, or support group",
"     </li>",
"     <li>",
"      Provide opportunities to meet other patients who have had the same or similar experiences",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The NAEPP also recommended that the patient should be given written instructions about how to use long-term control and rescue medications [",
"    <a class=\"abstract\" href=\"UTD.htm?12/31/12789/abstract/16\">",
"     16",
"    </a>",
"    ]. The instructions should include the dose, frequency of administration, guidelines for changing dose or adding medications, adverse effects to report to the clinician, and contact for securing urgent care, if needed.",
"   </p>",
"   <p>",
"    The NAEPP guidelines emphasize the importance of providing the patient with two written treatment plans: one for daily self-management and one for management of exacerbations [",
"    <a class=\"abstract\" href=\"UTD.htm?12/31/12789/abstract/16\">",
"     16",
"    </a>",
"    ]. Examples developed by the Panel are provided in the figure (",
"    <a class=\"graphic graphic_form graphicRef55900 \" href=\"UTD.htm?36/39/37498\">",
"     figure 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?38/63/39925?source=see_link\">",
"     \"Patient information: Asthma treatment in adolescents and adults (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      How to monitor body signs or symptoms",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      peak expiratory flow rate (PEFR) to detect increasing airflow obstruction as early as possible; early signs of airflow obstruction vary according to the individual and should be identified for each patient. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/53/854?source=see_link\">",
"       \"Peak expiratory flow rate monitoring in asthma\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?31/6/31841?source=see_link\">",
"       \"Patient information: How to use a peak flow meter (Beyond the Basics)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Clear instructions for initiating or modifying treatment when conditions change, such as new or worsened symptoms, or a drop in PEFR",
"     </li>",
"     <li>",
"      A list of steps to take when medicines are ineffective or if an emergency situation arises. The steps may include removing the precipitating trigger, giving medication, avoiding strenuous physical activity, and keeping the patient and family calm. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/9/44184?source=see_link\">",
"       \"Trigger control to enhance asthma management\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Specific criteria for seeking emergency medical care without delay, including a pattern of declining PEFR; failure of medications at home to control worsening symptoms; difficulty in walking, talking, or breathing (even if wheeze is absent); intercostal retractions; blue fingernails or lips.",
"     </li>",
"     <li>",
"      Observable signs that long-term therapy is less than optimal, such as sleep interruption",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      consistently low or highly variable PEFR. Such signs should be discussed with the clinician.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These general steps should be combined with instructions concerning other specific aspects of asthma care as outlined in separate topic reviews. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/15/31991?source=see_link\">",
"     \"What do patients need to know about their asthma?\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/26/18856?source=see_link\">",
"     \"The use of inhaler devices in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PATIENT ACTIVITIES TO ENHANCE COMPLIANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patient self-management of asthma or any chronic disease must be learned. Patients can be taught coping skills and problem-solving skills to use in increasing their compliance. The following approaches from a workbook developed for pulmonary patients at the University of Alabama at Birmingham are suggested; the figures can be printed and given to appropriate patients:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Activity 1 &ndash; Identify problems in taking medications (",
"      <a class=\"graphic graphic_table graphicRef81611 graphicRef56319 \" href=\"UTD.htm?23/56/24461\">",
"       table 1A-B",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Activity 2 &ndash; Take steps to solve medicine-taking problems (",
"      <a class=\"graphic graphic_table graphicRef70098 \" href=\"UTD.htm?2/63/3068\">",
"       table 2",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Activity 3 &ndash; Learn solutions to common problems (",
"      <a class=\"graphic graphic_table graphicRef80864 \" href=\"UTD.htm?5/13/5341\">",
"       table 3",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?6/21/6483?source=see_link\">",
"       \"Patient information: Reducing the costs of medicines (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?38/63/39925?source=see_link\">",
"       \"Patient information: Asthma treatment in adolescents and adults (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?30/25/31124?source=see_link\">",
"       \"Patient information: Trigger avoidance in asthma (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?31/6/31841?source=see_link\">",
"       \"Patient information: How to use a peak flow meter (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?28/25/29075?source=see_link\">",
"       \"Patient information: Asthma inhaler techniques in adults (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?43/3/44083?source=see_link\">",
"       \"Patient information: Asthma inhaler techniques in children (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Adherence to asthma medication regimens tends to be very poor, with the reported rates of nonadherence ranging from 30 to 70 percent. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Medication-related factors that contribute to poor adherence include difficulties with inhaler devices, complex regimens, side effects, cost of medication, dislike of medication, and distant pharmacies. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Reasons for nonadherence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Factors unrelated to medications that contribute to poor adherence include misunderstanding or lack of instruction about the medications, fears about side effects, dissatisfaction with health care professionals, anger about one's condition or its treatment, underestimation of severity, cultural and social issues, stigmatization, and forgetfulness or complacency. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Reasons for nonadherence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      One of the first, and most important, steps to improving adherence is to establish the goals of therapy in a collaborative fashion with the patient. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Improving adherence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Additional steps towards improving adherence include identifying and addressing reasons for nonadherence, clarifying the patient's expectations for treatment and addressing fears and concerns, simplifying the medical regimen, explaining how each medication works to control or prevent symptoms, and providing written instructions about long-term control and rescue medications. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Improving adherence'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12789/abstract/1\">",
"      Bender BG, Bender SE. Patient-identified barriers to asthma treatment adherence: responses to interviews, focus groups, and questionnaires. Immunol Allergy Clin North Am 2005; 25:107.",
"     </a>",
"    </li>",
"    <li>",
"     Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA) 2012. Full text available online at: www.ginasthma.org (Accessed on March 12, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12789/abstract/3\">",
"      Rand CS, Wise RA. Measuring adherence to asthma medication regimens. Am J Respir Crit Care Med 1994; 149:S69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12789/abstract/4\">",
"      Thoonen BP, Schermer TR, Van Den Boom G, et al. Self-management of asthma in general practice, asthma control and quality of life: a randomised controlled trial. Thorax 2003; 58:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12789/abstract/5\">",
"      Williams LK, Joseph CL, Peterson EL, et al. Patients with asthma who do not fill their inhaled corticosteroids: a study of primary nonadherence. J Allergy Clin Immunol 2007; 120:1153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12789/abstract/6\">",
"      Wells K, Pladevall M, Peterson EL, et al. Race-ethnic differences in factors associated with inhaled steroid adherence among adults with asthma. Am J Respir Crit Care Med 2008; 178:1194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12789/abstract/7\">",
"      Billimek J, Sorkin DH. Self-reported neighborhood safety and nonadherence to treatment regimens among patients with type 2 diabetes. J Gen Intern Med 2012; 27:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12789/abstract/8\">",
"      Creer, TL. Understanding and dealing with noncompliance in asthma. J Respir Dis 1991; 12:S43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12789/abstract/9\">",
"      Kohler CL, Davies SL, Bailey WC. Self-management and other behavioral aspects of asthma. Curr Opin Pulm Med 1996; 2:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12789/abstract/10\">",
"      Tan H, Sarawate C, Singer J, et al. Impact of asthma controller medications on clinical, economic, and patient-reported outcomes. Mayo Clin Proc 2009; 84:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12789/abstract/11\">",
"      Berg J, Dunbar-Jacob J, Rohay JM. Compliance with inhaled medications: the relationship between diary and electronic monitor. Ann Behav Med 1998; 20:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12789/abstract/12\">",
"      Bosley CM, Parry DT, Cochrane GM. Patient compliance with inhaled medication: does combining beta-agonists with corticosteroids improve compliance? Eur Respir J 1994; 7:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12789/abstract/13\">",
"      Hindi-Alexander MC, Throm J, Middleton E Jr. Collaborative asthma self-management. Evaluation designs. Clin Rev Allergy 1987; 5:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12789/abstract/14\">",
"      Apter AJ, Wang X, Bogen DK, et al. Problem solving to improve adherence and asthma outcomes in urban adults with moderate or severe asthma: a randomized controlled trial. J Allergy Clin Immunol 2011; 128:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12789/abstract/15\">",
"      Wilson SR, Strub P, Buist AS, et al. Shared treatment decision making improves adherence and outcomes in poorly controlled asthma. Am J Respir Crit Care Med 2010; 181:566.",
"     </a>",
"    </li>",
"    <li>",
"     National Asthma Education and Prevention Program: Expert Panel Report III: Guidelines for the diagnosis and management of asthma. Bethesda, MD. National Heart, Lung, and Blood Institute, 2007. (NIH publication no. 08-4051) www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm (Accessed on September 01, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12789/abstract/17\">",
"      Borrelli B, Riekert KA, Weinstein A, Rathier L. Brief motivational interviewing as a clinical strategy to promote asthma medication adherence. J Allergy Clin Immunol 2007; 120:1023.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 556 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-110.170.48.130-F96105F60D-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_31_12789=[""].join("\n");
var outline_f12_31_12789=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H6\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      REASONS FOR NONADHERENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      IMPROVING ADHERENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PATIENT ACTIVITIES TO ENHANCE COMPLIANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/556\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/556|Form\">",
"      <a href=\"#\" title=\"FORMS\">",
"       FORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_form\" href=\"UTD.htm?36/39/37498\" title=\"figure 1\">",
"      Asthma action plan",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/556|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?26/47/27387\" title=\"table 1A\">",
"      Asthma adherence I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?37/3/37948\" title=\"table 1B\">",
"      Asthma adherence II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/63/3068\" title=\"table 2\">",
"      Asthma adherence III",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/13/5341\" title=\"table 3\">",
"      Asthma adherence IV",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?28/25/29075?source=related_link\">",
"      Patient information: Asthma inhaler techniques in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?43/3/44083?source=related_link\">",
"      Patient information: Asthma inhaler techniques in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/63/39925?source=related_link\">",
"      Patient information: Asthma treatment in adolescents and adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?31/6/31841?source=related_link\">",
"      Patient information: How to use a peak flow meter (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?6/21/6483?source=related_link\">",
"      Patient information: Reducing the costs of medicines (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/25/31124?source=related_link\">",
"      Patient information: Trigger avoidance in asthma (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/53/854?source=related_link\">",
"      Peak expiratory flow rate monitoring in asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/26/18856?source=related_link\">",
"      The use of inhaler devices in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/9/44184?source=related_link\">",
"      Trigger control to enhance asthma management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/15/31991?source=related_link\">",
"      What do patients need to know about their asthma?",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_31_12790="Mucoceles";
var content_f12_31_12790=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F75671&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F75671&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 540px\">",
"   <div class=\"ttl\">",
"    Mucoceles",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 520px; height: 371px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Mucocele on the tongue of&nbsp;7-year-old (A and B) and lower lip of 8.5-year-old (C and D).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Martha Ann Keels, DDS, PhD, Duke Pediatric Dentistry.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_31_12790=[""].join("\n");
var outline_f12_31_12790=null;
var title_f12_31_12791="Aphthous lesions Crohns Endosc";
var content_f12_31_12791=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F78561%7EGAST%2F68093%7EGAST%2F71769&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F78561%7EGAST%2F68093%7EGAST%2F71769&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Aphthous lesions in Crohn's disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 230px; height: 221px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Colonoscopy demonstrates small discreet aphthous lesions (superficial ulcerations) that are characteristic of early lesions in Crohn's disease.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of James B McGee, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Linear ulcerations in Crohn's disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 368px; height: 183px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Colonoscopy shows linear ulcers that can course for several centimeters along the longitudinal axis of the colon in Crohn's disease.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of James B McGee, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Asymmetric distribution of lesions in Crohn's disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 366px; height: 183px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Colonoscopy in Crohn's disease demonstrates the characteristic patchy erythema (left panel) and ulceration (right panel) that occur next to areas of normal mucosa.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of James B McGee, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_31_12791=[""].join("\n");
var outline_f12_31_12791=null;
var title_f12_31_12792="Rifabutin: Pediatric drug information";
var content_f12_31_12792=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Rifabutin: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?31/63/32760?source=see_link\">",
"    see \"Rifabutin: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?39/32/40452?source=see_link\">",
"    see \"Rifabutin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F218030\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Mycobutin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F218031\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Mycobutin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1049708\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antibiotic, Miscellaneous",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antitubercular Agent",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1049702\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?31/63/32760?source=see_link\">",
"      see \"Rifabutin: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infants and Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Mycobacterium avium",
"     </i>",
"     complex (MAC) (CDC, 2009):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Treatment, add-on therapy for severe infection: 10-20 mg/kg once daily (maximum: 300 mg)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Prophylaxis  for first episode (HIV-positive/exposed patients &ge;6 years ): 300 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Prophylaxis for recurrence (HIV positive-/exposed patients): 5 mg/kg (maximum dose: 300 mg) once daily as an optional add-on to primary therapy of clarithromycin and ethambutol",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tuberculosis, treatment (alternative to rifampin): 10-20 mg/kg (maximum dose: 300 mg) once daily or intermittently 2-3 times weekly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adolescents and Adults (CDC, 2009a):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Disseminated MAC in advanced HIV infection:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Prophylaxis: 300 mg once daily or 150 mg twice daily to reduce gastrointestinal upset",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Treatment: 300 mg once daily as an optional add-on to primary therapy of clarithromycin and ethambutol",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tuberculosis (alternative to rifampin):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Prophylaxis of LTBI: 300 mg once daily for 4 months",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Treatment of active TB: 300 mg once daily or intermittently 2-3 times weekly as part of multidrug regimen",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment for concurrent efavirenz (no concomitant protease inhibitor):",
"     </b>",
"     Adolescents and Adults: Increase rifabutin dose to 450-600 mg daily or 600 mg 3 times/week",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment for concurrent nelfinavir, amprenavir, indinavir:",
"     </b>",
"     Adolescents and Adults: Reduce rifabutin dose to 150 mg/day; no change in dose if administered twice weekly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment in renal impairment:",
"     </b>",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute: Reduce dose by 50%",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F218010\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mycobutin&reg;: 150 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F217996\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1049711\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: May administer with or without food or mix with applesauce if patient unable to swallow capsule; administer with food to decrease GI upset",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F8014817\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Capsules should be stored in a well-closed container at 25&deg;C (77&deg;F) with excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86 &deg;F)",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1049710\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prevention of disseminated",
"     <i>",
"      Mycobacterium avium",
"     </i>",
"     complex (MAC) in patients with advanced HIV infection (FDA approved in adults); has also been utilized in multiple drug regimens for treatment of MAC; alternative to rifampin as prophylaxis for latent tuberculosis infection (LTBI) or part of multidrug regimen for treatment active tuberculosis infection; alternative as agent for prophylaxis of",
"     <i>",
"      Mycobacterium avium",
"     </i>",
"     complex in children &gt;6 years; add-on therapy for severe",
"     <i>",
"      Mycobacterium avium",
"     </i>",
"     complex infection",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F218076\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Rifabutin may be confused with rifampin",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F218074\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Headache, fever",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, dyspepsia, eructation, flatulence, nausea, taste perversion, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Discoloration of urine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Leukopenia, neutropenia, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: ALT increased, AST increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Myalgia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Aphasia, arthralgia, chest pain, confusion, dyspnea, flu-like syndrome, hepatitis, hemolysis, myositis, parasthesia, seizures, skin discoloration, T-wave abnormalities, uveitis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1049715\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to rifabutin, any component, or other rifamycin",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1049701\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with liver or renal impairment; modify dose in patients with Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute. Rifabutin is a CYP3A3/4 isoenzyme inducer which may reduce the plasma concentrations of itraconazole, clarithromycin, and saquinavir. CYP3A3/4 isoenzyme inhibitors such as fluconazole and clarithromycin may elevate levels of rifabutin increasing the risk of adverse reactions. Monitor patients, and in some cases, reduce the rifabutin dose when coadministered with fluconazole or clarithromycin. Rifabutin decreases plasma concentrations of delavirdine; delavirdine increases plasma concentrations of rifabutin (coadministration of rifabutin and delavirdine is not recommended). May be associated with neutropenia and/or thrombocytopenia (rarely); consider hematologic monitoring and discontinue permanently if signs of thrombocytopenia (eg, petechial rash) occur.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1049700\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Rifabutin as a single agent must not be administered to patients with active tuberculosis since its use may lead to the development of tuberculosis that is resistant to both rifabutin and rifampin; rifabutin should be discontinued in patients with AST &gt;3x ULN (symptomatic) or &ge;5x ULN (regardless of symptoms) or if significant bilirubin and/or alkaline phosphatase elevations occur.  Tiny, asymptomatic peripheral and central corneal deposits have been observed during routine ophthalmologic exams in HIV-positive patients receiving rifabutin.",
"     <i>",
"      C. difficile",
"     </i>",
"     -associated diarrhea has been reported with use of rifabutin.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F218062\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP1A2 (minor), CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Induces",
"     </b>",
"     CYP3A4 (strong)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F218005\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfentanil: Rifamycin Derivatives may decrease the serum concentration of Alfentanil.  Management: Monitor closely for decreased alfentanil effectiveness.  Increased alfentanil doses will likely be needed.  Alternatively, changing from alfentanil to a different opioid anesthetic (e.g., sufentanil) may also be considered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amiodarone: Rifamycin Derivatives may increase the metabolism of Amiodarone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Angiotensin II Receptor Blockers: Rifamycin Derivatives may increase the metabolism of Angiotensin II Receptor Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Candesartan; Eprosartan; Olmesartan; Telmisartan; Valsartan.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antiemetics (5HT3 Antagonists): Rifamycin Derivatives may increase the metabolism of Antiemetics (5HT3 Antagonists).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dolasetron; Granisetron; Palonosetron.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antifungal Agents (Azole Derivatives, Systemic): Rifamycin Derivatives may decrease the serum concentration of Antifungal Agents (Azole Derivatives, Systemic). Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Rifamycin Derivatives. Only rifabutin appears to be affected.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Apixaban: CYP3A4 Inducers (Strong) may decrease the serum concentration of Apixaban.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aprepitant: Rifamycin Derivatives may increase the metabolism of Aprepitant.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inducers may decrease the serum concentration of ARIPiprazole.  Management: Double the oral aripiprazole dose and closely monitor clinical response.  Reduce the oral aripiprazole dose to 10-15 mg/day if the inducer is discontinued. Avoid use of CYP3A4 inducers for more than 14 days with extended-release injectable aripiprazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atazanavir: May increase serum concentrations of the active metabolite(s) of Rifabutin. Atazanavir may increase the serum concentration of Rifabutin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atovaquone: Rifamycin Derivatives may decrease the serum concentration of Atovaquone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Axitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Axitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: Rifamycin Derivatives may increase the metabolism of Barbiturates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bedaquiline: CYP3A4 Inducers (Strong) may decrease the serum concentration of Bedaquiline.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzodiazepines (metabolized by oxidation): Rifamycin Derivatives may increase the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: May increase the serum concentration of Rifabutin. Rifabutin may decrease the serum concentration of Boceprevir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bortezomib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Bortezomib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Brentuximab Vedotin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Brentuximab Vedotin. Specifically, concentrations of the active monomethyl auristatin E (MMAE) component may be decreased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BusPIRone: Rifamycin Derivatives may decrease the serum concentration of BusPIRone.  Management: The degree to which rifampin alters buspirone concentrations warrants the consideration of an alternative to buspirone that is not metabolized by CYP3A4.  If these agents are used together, buspirone dose adjustments may be needed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cabozantinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Cabozantinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers: Rifamycin Derivatives may increase the metabolism of Calcium Channel Blockers. This primarily affects oral forms of calcium channel blockers.  Management: The labeling for some U.S. and Canadian calcium channel blockers contraindicate use with rifampin however recommendations vary. Consult appropriate labeling.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Clevidipine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clopidogrel: Rifamycin Derivatives may enhance the therapeutic effect of Clopidogrel.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cobicistat: Rifabutin may decrease the serum concentration of Cobicistat.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Estrogens): Rifamycin Derivatives may decrease the serum concentration of Contraceptives (Estrogens). Contraceptive failure is possible.  Management: Use of an alternative, nonhormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Progestins): Rifamycin Derivatives may decrease the serum concentration of Contraceptives (Progestins). Contraceptive failure is possible.  Management: Contraceptive failure is possible.  Use of an alternative, nonhormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): Rifamycin Derivatives may increase the metabolism of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Crizotinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Crizotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Rifamycin Derivatives may increase the metabolism of CycloSPORINE (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Substrates: CYP3A4 Inducers (Strong) may increase the metabolism of CYP3A4 Substrates.  Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dapsone (Systemic): Rifamycin Derivatives may increase the metabolism of Dapsone (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Darunavir: May increase serum concentrations of the active metabolite(s) of Rifabutin. Darunavir may increase the serum concentration of Rifabutin. Rifabutin may increase the serum concentration of Darunavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Dasatinib.  Management: Avoid when possible. If such a combination cannot be avoided, consider increasing dasatinib dose and monitor clinical response and toxicity closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Delavirdine: May decrease the metabolism of Rifamycin Derivatives. Rifamycin Derivatives may increase the metabolism of Delavirdine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Disopyramide: Rifamycin Derivatives may decrease the serum concentration of Disopyramide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dronedarone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Dronedarone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Efavirenz: May decrease the serum concentration of Rifabutin. Rifabutin may decrease the serum concentration of Efavirenz. Management: If efavirenz is to be used with daily rifabutin, increase the planned rifabutin adult dose by 50%.  If used with regimens where rifabutin is administered 2-3 times per week, consider doubling the rifabutin dose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Elvitegravir: Rifabutin may decrease the serum concentration of Elvitegravir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Enzalutamide: CYP3A4 Inducers (Strong) may decrease the serum concentration of Enzalutamide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etravirine: Rifabutin may decrease the serum concentration of Etravirine.  Management: Avoid concomitant use with rifabutin if a protease inhibitor/ritonavir combination is also used.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: CYP3A4 Inducers (Strong) may decrease the serum concentration of Everolimus.  Management: Avoid concurrent use of strong CYP3A4 inducers, but if strong CYP3A4 inducers cannot be avoided, consider gradually (in 5 mg increments) increasing the everolimus dose from 10 mg/day to 20 mg/day (adult doses).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Exemestane: CYP3A4 Inducers (Strong) may decrease the serum concentration of Exemestane.  Management: Exemestane U.S. product labeling recommends using an increased dose (50 mg/day) in patients receiving concurrent strong CYP3A4 inducers. The Canadian product labeling does not recommend a dose adjustment  with concurrent use of strong CYP3A4 inducers.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FentaNYL: Rifamycin Derivatives may decrease the serum concentration of FentaNYL.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluconazole: May decrease the metabolism of Rifamycin Derivatives. This appears only affect rifabutin. Rifamycin Derivatives may increase the metabolism of Fluconazole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosamprenavir: May increase serum concentrations of the active metabolite(s) of Rifabutin. Fosamprenavir may increase the serum concentration of Rifabutin. Rifabutin may increase the serum concentration of Fosamprenavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: Rifamycin Derivatives may decrease the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gefitinib: Rifamycin Derivatives may increase the metabolism of Gefitinib.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     GuanFACINE: CYP3A4 Inducers (Strong) may decrease the serum concentration of GuanFACINE.  Management: Consider increasing the guanfacine dose by 2-fold when adding a strong CYP3A4 inducer.  Titrate the guanfacine dose up to a max of 8 mg/day when starting guanfacine in a patient who is taking a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HMG-CoA Reductase Inhibitors: Rifamycin Derivatives may decrease the serum concentration of HMG-CoA Reductase Inhibitors.  Management: Consider use of noninteracting antilipemic agents (note: pitavastatin concentrations may increase with rifamycin treatment).  Monitor for altered HMG-CoA reductase inhibitor effects. Rifabutin and fluvastatin, or possibly pravastatin, may pose lower risk.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Pitavastatin; Rosuvastatin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ifosfamide: CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Ifosfamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Imatinib: Rifamycin Derivatives may decrease the serum concentration of Imatinib.  Management: Avoid concurrent use of imatinib with the rifamycin derivatives when possible.  If such a combination must be used, increase imatinib dose by at least 50% and monitor the patient's clinical response closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Indinavir: May increase serum concentrations of the active metabolite(s) of Rifabutin. Indinavir may increase the serum concentration of Rifabutin. Rifabutin may decrease the serum concentration of Indinavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Isoniazid: Rifamycin Derivatives may enhance the hepatotoxic effect of Isoniazid. Even so, this is a frequently employed combination regimen.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ivacaftor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ixabepilone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ixabepilone.  Management: Avoid this combination whenever possible.  If this combination must be used, a gradual increase in ixabepilone dose from 40 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     to 60 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     (given as a 4-hour infusion), as tolerated, should be considered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lapatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lapatinib.  Management: If therapy overlap cannot be avoided, consider titrating lapatinib gradually from 1,250 mg/day up to 4,500 mg/day (HER2 positive metastatic breast cancer) or 1,500 mg/day up to 5,500 mg/day (hormone receptor/HER2 positive breast cancer) as tolerated.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Linagliptin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Linagliptin.  Management: Strongly consider using an alternative to any strong CYP3A4 inducer in patients who are being treated with linagliptin. If this combination is used, monitor patients closely for evidence of reduced linagliptin effectiveness.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lopinavir: May increase serum concentrations of the active metabolite(s) of Rifabutin. Lopinavir may increase the serum concentration of Rifabutin. Rifabutin may increase the serum concentration of Lopinavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lurasidone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lurasidone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May decrease the metabolism of Rifamycin Derivatives.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Systemic); Fidaxomicin; Spiramycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Maraviroc: CYP3A4 Inducers (Strong) may decrease the serum concentration of Maraviroc.  Management: Increase maraviroc adult dose to 600 mg twice daily when used with strong CYP3A4 inducers. This does not apply to patients also receiving strong CYP3A4 inhibitors. Do not use maraviroc with strong CYP3A4 inducers in patients with Clcr less than 30 mL/min.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Mifepristone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Morphine (Systemic): Rifamycin Derivatives may decrease the serum concentration of Morphine (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mycophenolate: Rifamycin Derivatives may decrease the serum concentration of Mycophenolate. Specifically, rifamycin derivatives may decrease the concentration of the active metabolite mycophenolic acid.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nelfinavir: May increase serum concentrations of the active metabolite(s) of Rifabutin. Nelfinavir may increase the serum concentration of Rifabutin. Rifabutin may decrease the serum concentration of Nelfinavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nevirapine: May decrease the serum concentration of Rifabutin. Nevirapine may increase the serum concentration of Rifabutin. Rifabutin may decrease the serum concentration of Nevirapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nilotinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Nilotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pazopanib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Pazopanib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: CYP3A4 Inducers (Strong) may decrease the serum concentration of Perampanel.  Management: Avoid use of perampanel with strong CYP3A inducers other than enzyme-inducing antiepileptic drugs (EIAEDs).  Increase perampanel starting dose to 4 mg/day when used with EIAEDs such as phenytoin, carbamazepine, or oxcarbazepine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: Rifamycin Derivatives may decrease the serum concentration of Phenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pitavastatin: Rifamycin Derivatives may increase the serum concentration of Pitavastatin.  Management: Limit pitavastatin dose to a maximum of 2 mg/day with concurrent rifampin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: CYP3A4 Inducers (Strong) may decrease the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ponatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ponatinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Praziquantel: CYP3A4 Inducers (Strong) may decrease the serum concentration of Praziquantel.  Management: Avoid concomitant use of praziquantel with strong CYP3A4 inducers. Discontinue rifampin 4 weeks prior to initiation of praziquantel therapy. Rifampin may be resumed the day following praziquantel completion.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: Rifamycin Derivatives may decrease the serum concentration of Propafenone.  Management: Monitor propafenone serum concentrations closely with rifamycin initiation/dose adjustments/discontinuation. Propafenone serum concentrations/therapeutic effects  may decrease with rifamycins. Propafenone dose adjustments may be necessary.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: Rifamycin Derivatives may decrease the serum concentration of QuiNIDine.  Management: Consider alternatives to combination treatment with quinidine and rifampin due to large potential decreases in quinidine concentrations. Monitor for decreased quinidine concentrations/effects with initiation/dose increase of any rifamycin derivative.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Raltegravir: Rifabutin may decrease the serum concentration of Raltegravir. Specifically, minimum serum concentrations (Cmin) may be reduced.  Total raltegravir exposure (i.e., AUC) may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ramelteon: Rifamycin Derivatives may increase the metabolism of Ramelteon.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranolazine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ranolazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Regorafenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Regorafenib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Repaglinide: Rifamycin Derivatives may increase the metabolism of Repaglinide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rilpivirine: Rifamycin Derivatives may decrease the serum concentration of Rilpivirine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ritonavir: May increase serum concentrations of the active metabolite(s) of Rifabutin. Ritonavir may increase the serum concentration of Rifabutin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: CYP3A4 Inducers (Strong) may decrease the serum concentration of Rivaroxaban.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: CYP3A4 Inducers (Strong) may decrease the serum concentration of Roflumilast.  Management: Roflumilast U.S. prescribing information recommends against combining strong CYP3A4 inducers with roflumilast.  The Canadian product monograph makes no such recommendation but notes that such agents may reduce roflumilast therapeutic effects.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RomiDEPsin: CYP3A4 Inducers (Strong) may decrease the serum concentration of RomiDEPsin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saquinavir: May increase serum concentrations of the active metabolite(s) of Rifabutin. Saquinavir may increase the serum concentration of Rifabutin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inducers may decrease the serum concentration of Saxagliptin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SORAfenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of SORAfenib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SUNItinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of SUNItinib.  Management: Avoid when possible. If such a combination cannot be avoided, consider increasing sunitinib dose and monitor clinical response and toxicity closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Systemic): Rifamycin Derivatives may increase the metabolism of Tacrolimus (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tadalafil: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tadalafil.  Management: Erectile dysfunction: monitor for decreased effectiveness - no standard dose adjustments recommended.  Avoid use of tadalafil for pulmonary arterial hypertension in patients receiving a strong CYP3A4 inducer.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tamoxifen: Rifamycin Derivatives may increase the metabolism of Tamoxifen.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: Rifabutin may decrease the serum concentration of Telaprevir. Telaprevir may increase the serum concentration of Rifabutin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Temsirolimus: Rifamycin Derivatives may decrease the serum concentration of Temsirolimus. Rifamycins will likely cause an even greater decrease in the concentration of the active metabolite sirolimus.  Management: Temsirolimus prescribing information recommends against coadministration with strong CYP3A4 inducers such as rifampin; however, if concurrent therapy is necessary, an increase in temsirolimus adult dose to 50 mg/week should be considered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ticagrelor: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Ticagrelor. CYP3A4 Inducers (Strong) may decrease the serum concentration of Ticagrelor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: May increase serum concentrations of the active metabolite(s) of Rifabutin. Tipranavir may increase the serum concentration of Rifabutin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tofacitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tolvaptan.  Management: If concurrent use is necessary, increased doses of tolvaptan (with close monitoring for toxicity and clinical response) may be needed.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Toremifene: CYP3A4 Inducers (Strong) may decrease the serum concentration of Toremifene.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 24 hours after cessation of antibacterial agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ulipristal: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ulipristal.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vandetanib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Vandetanib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vemurafenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Vemurafenib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine (Liposomal): CYP3A4 Inducers (Strong) may decrease the serum concentration of VinCRIStine (Liposomal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Rifamycin Derivatives may increase the metabolism of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: May increase the serum concentration of Rifamycin Derivatives. Rifamycin Derivatives may decrease the serum concentration of Voriconazole.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zaleplon: Rifamycin Derivatives may increase the metabolism of Zaleplon.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: Rifamycin Derivatives may decrease the serum concentration of Zolpidem.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zuclopenthixol: CYP3A4 Inducers (Strong) may decrease the serum concentration of Zuclopenthixol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1049717\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     High-fat meal may decrease the rate but not the extent of absorption",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F218006\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F14079708\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were seen in some animal reproduction studies.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1049707\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Periodic liver function tests, CBC with differential, platelet count, hemoglobin, hematocrit, ophthalmologic exam, number and type of stools/day for diarrhea",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1049699\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits DNA-dependent RNA polymerase at the beta subunit which prevents chain initiation",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1049714\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Readily absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: To body tissues including the lungs, liver, spleen, eyes, and kidneys",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     V",
"     <sub>",
"      d",
"     </sub>",
"     : Adults: 9.3 &plusmn; 1.5 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 85%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatically to 5 metabolites; predominantly 25-O-desacetyl-rifabutin (antimicrobial activity equivalent to parent drug; serum AUC 10% of parent drug) and 31-hydroxy-rifabutin (serum AUC 7% of parent drug)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: 20% in HIV patients",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life, terminal: 45 hours (range: 16-69 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: 2-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Renal and biliary clearance of unchanged drug is 10%; 30% excreted in feces; 53% excreted in urine",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1049706\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?39/32/40452?source=see_link\">",
"      see \"Rifabutin: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May discolor skin, urine, feces, tears, perspiration, or other body fluids to a brown-orange color; soft contact lenses may be permanently stained. Notify physician of any severe flu-like symptoms, nausea, vomiting, persistent diarrhea, dark urine, unusual bleeding or bruising, or any eye problems",
"    </p>",
"   </div>",
"   <div class=\"block exp drugH1Div\" id=\"F11447911\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Extemporaneous Preparations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A 20 mg/mL rifabutin oral suspension may be made with capsules and a 1:1 mixture of Ora-Sweet&reg; and Ora-Plus&reg;. Empty the the powder from eight 150 mg rifabutin capsules into a glass mortar; add 20 mL of vehicle and mix to a uniform paste. Mix while adding vehicle in incremental proportions to",
"     <b>",
"      almost",
"     </b>",
"     60 mL; transfer to a calibrated bottle, rinse mortar with vehicle, and add quantity of vehicle sufficient to make 60 mL. Label \"shake well\". Stable for 12 weeks at 4&deg;C, 25&deg;C, 30&deg;C, and 40&deg;C.",
"    </p>",
"    <div class=\"reference\">",
"     Haslam JL, Egodage KL, Chen Y, et al, \"Stability of Rifabutin in Two Extemporaneously Compounded Oral Liquids,\"",
"     <i>",
"      Am J Health Syst Pharm",
"     </i>",
"     , 1999, 56(4):333-6.",
"     <span class=\"pubmed-id\">",
"      10690216",
"     </span>",
"    </div>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Adult Prevention and Treatment of Opportunistic Infections Guidelines Working Group, \"Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents. March 24, 2009,\"",
"      <i>",
"       MMWR",
"      </i>",
"      , 2009; 58 (early release): 1-198. Available at: file://www.cdc.gov/mmwr/preview/mmwrhtml/rr58e324a1.htm. Accessed May 21, 2009.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Guidelines for the Prevention and Treatment of Opportunistic Infections Among HIV-Exposed and HIV-Infected Children,\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2009, 58(RR-11):1-166. Available at",
"      <a href=\"file://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf%20\" target=\"_blank\">",
"       file://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf",
"      </a>",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/31/12792/abstract-text/19730409/pubmed\" id=\"19730409\" target=\"_blank\">",
"        19730409",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Krause PJ, Hight DW, Schwartz AN, et al, &ldquo;Successful Management of",
"      <i>",
"       Mycobacterium intracellulare",
"      </i>",
"      Pneumonia in a Child,&rdquo;",
"      <i>",
"       Pediatr Infect Dis",
"      </i>",
"      , 1986, 5(2):269-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/31/12792/abstract-text/3952014/pubmed\" id=\"3952014\" target=\"_blank\">",
"        3952014",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Levin RH and Bolinger AM, &ldquo;Treatment of Nontuberculous Mycobacterial Infections in Pediatric Patients,&rdquo;",
"      <i>",
"       Clin Pharm",
"      </i>",
"      , 1988, 7(7):545-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/31/12792/abstract-text/2843317/pubmed\" id=\"2843317\" target=\"_blank\">",
"        2843317",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Starke JR and Correa AG, &ldquo;Management of Mycobacterial Infection and Disease in Children,&rdquo;",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 1995, 14(6):455-70.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/31/12792/abstract-text/7667049/pubmed\" id=\"7667049\" target=\"_blank\">",
"        7667049",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Working Group on Guidelines for the Prevention and Treatment of Opportunistic Infections Among HIV-Exposed and HIV-Infected Children, \"Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Exposed and HIV-Infected Children [DRAFT]. June 20, 2008,\" 2008, 1-250. Available at: file://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf. Accessed May 21, 2009.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12766 Version 42.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-67CE5B8581-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_31_12792=[""].join("\n");
var outline_f12_31_12792=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218030\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218031\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049708\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049702\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218010\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217996\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049711\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8014817\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049710\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218076\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218074\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049715\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049701\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049700\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218062\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218005\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049717\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218006\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14079708\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049707\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049699\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049714\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049706\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11447911\">",
"      Extemporaneous Preparations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12766\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12766|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?31/63/32760?source=related_link\">",
"      Rifabutin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?39/32/40452?source=related_link\">",
"      Rifabutin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_31_12793="Management of classical Hodgkin lymphoma during pregnancy";
var content_f12_31_12793=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of classical Hodgkin lymphoma during pregnancy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/31/12793/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/31/12793/contributors\">",
"     Joachim Yahalom, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/31/12793/contributors\">",
"     Steven Horwitz, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/31/12793/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/31/12793/contributors\">",
"     Arnold S Freedman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/31/12793/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/31/12793/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/31/12793/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/31/12793/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although Hodgkin lymphoma (formerly called Hodgkin's disease, HL) accounts for only 10 percent of all lymphomas, it is one of the most common lymphoma subtypes diagnosed during pregnancy, largely because the peak incidence of HL coincides with female reproductive age. However, the association between HL and pregnancy is uncommon. HL is diagnosed in approximately 1:1000 to 1:6000 pregnancies and accounts for 3 percent or fewer of all patients with HL [",
"    <a class=\"abstract\" href=\"UTD.htm?12/31/12793/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/13/15578?source=see_link&amp;anchor=H2#H2\">",
"     \"Epidemiology, pathologic features, and diagnosis of classical Hodgkin lymphoma\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As a result, there are few large series that have evaluated the many issues that must be addressed in such women. This topic will review the clinical presentation and management of HL during pregnancy, the interaction of malignancy and pregnancy, and the effects of treatment on the developing fetus and delivered infant. The diagnosis and management of HL in the nonpregnant adult is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/33/29206?source=see_link\">",
"     \"Initial evaluation and diagnosis of Hodgkin lymphoma in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/12/13512?source=see_link\">",
"     \"Overview of the treatment of classical Hodgkin lymphoma in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnant patients with HL present in a similar fashion to nonpregnant patients with HL (eg, painless lymphadenopathy). Of importance, some signs and symptoms due to the HL (eg, fatigue, shortness of breath, anemia, thrombocytopenia) overlap with common signs and symptoms seen during pregnancy, potentially resulting in a delay of diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/35/568?source=see_link\">",
"     \"Clinical presentation and patterns of disease distribution in classical Hodgkin lymphoma in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/56/38793?source=see_link\">",
"     \"Thrombocytopenia in pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Retrospective case series have described the clinical presentation of pregnant women with HL, with generally similar findings [",
"    <a class=\"abstract\" href=\"UTD.htm?12/31/12793/abstract/1,3-5\">",
"     1,3-5",
"    </a>",
"    ]. One of the larger series consisted of 48 women (median age 26 years) with 50 pregnancies occurring during active HL [",
"    <a class=\"abstract\" href=\"UTD.htm?12/31/12793/abstract/3\">",
"     3",
"    </a>",
"    ]. The diagnosis of HL was made in 12 patients before conception, in 10 during pregnancy, and in 27 within nine months after delivery or pregnancy termination. Each pregnant woman was matched with three nonpregnant HL controls. The stage at diagnosis did not differ significantly from the controls: stage I, 25 percent; stage II, 46 percent; stage III, 17 percent; and stage IV, 12 percent (",
"    <a class=\"graphic graphic_table graphicRef73699 \" href=\"UTD.htm?36/59/37819\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/35/568?source=see_link\">",
"     \"Clinical presentation and patterns of disease distribution in classical Hodgkin lymphoma in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The presence of B symptoms (ie, fever, night sweats, or weight loss exceeding 10 percent of body weight) is variable. While most patients from North American series have presented without B symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?12/31/12793/abstract/1,4-6\">",
"     1,4-6",
"    </a>",
"    ], one report from Mexico described B symptoms in 10 of 14 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?12/31/12793/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/37/14935?source=see_link&amp;anchor=H13#H13\">",
"     \"Staging and prognosis of Hodgkin lymphoma\", section on 'Criteria for B symptoms'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H96544367\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of HL is made based upon the pathologic evaluation of involved tissue, usually a lymph node biopsy. An excisional lymph node biopsy, performed under local or general anesthesia, is preferred and the risk of anesthesia and biopsy is similar to that of healthy pregnant women [",
"    <a class=\"abstract\" href=\"UTD.htm?12/31/12793/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/33/29206?source=see_link&amp;anchor=H3#H3\">",
"     \"Initial evaluation and diagnosis of Hodgkin lymphoma in adults\", section on 'Tissue biopsy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The pathologic subtype of HL diagnosed during pregnancy is consistent with that commonly seen in women of reproductive age. As an example, in a series of 17 women with HL during pregnancy, 13 were classified as nodular sclerosis type, three as mixed cellularity type, and one was unclassified [",
"    <a class=\"abstract\" href=\"UTD.htm?12/31/12793/abstract/5\">",
"     5",
"    </a>",
"    ]. A similar predominance of nodular sclerosis type has been noted in other reports [",
"    <a class=\"abstract\" href=\"UTD.htm?12/31/12793/abstract/1,4\">",
"     1,4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/13/15578?source=see_link&amp;anchor=H12#H12\">",
"     \"Epidemiology, pathologic features, and diagnosis of classical Hodgkin lymphoma\", section on 'Morphology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     STAGING DURING PREGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;HL is staged using the Ann Arbor staging system (",
"    <a class=\"graphic graphic_table graphicRef73699 \" href=\"UTD.htm?36/59/37819\">",
"     table 1",
"    </a>",
"    ). For women with HL diagnosed during pregnancy, the recommended staging studies have evolved with changing technology and therapeutic options. The goal of staging in this setting is to provide the clinician and patient with enough information to guide management while limiting the risks to the fetus.",
"   </p>",
"   <p>",
"    The initial staging evaluation should include (",
"    <a class=\"graphic graphic_table graphicRef81526 \" href=\"UTD.htm?3/47/3836\">",
"     table 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A single",
"      <span class=\"nowrap\">",
"       posterior/anterior",
"      </span>",
"      view chest x-ray with adequate abdominal shielding",
"     </li>",
"     <li>",
"      Laboratory studies including a complete blood count, erythrocyte sedimentation rate (ESR), serum creatinine concentration, serum liver enzymes, and HIV serology. Of importance, ESR is often significantly elevated during normal pregnancy. &nbsp;",
"     </li>",
"     <li>",
"      Evaluation of the abdomen with magnetic resonance imaging (MRI) or ultrasound",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Evaluation of the abdomen with MRI is generally preferred to ultrasound, as it can evaluate nodes, liver, and spleen with good accuracy. Although there are limited data regarding its safety in this setting, it is thought that MRI is probably safe in the pregnant patient [",
"    <a class=\"abstract\" href=\"UTD.htm?12/31/12793/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. Abdominal ultrasound is known to be safe in the pregnant population, but is much less sensitive than MRI. In contrast, computed tomography (CT) scan exposes the fetus to potentially harmful radiation and therefore is rarely performed if MRI and abdominal ultrasound are available. Positron emission tomography (PET) is contraindicated [",
"    <a class=\"abstract\" href=\"UTD.htm?12/31/12793/abstract/12\">",
"     12",
"    </a>",
"    ]. The use of diagnostic imaging procedures during pregnancy is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/29/28120?source=see_link\">",
"     \"Diagnostic imaging procedures during pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Bone marrow biopsy can be safely performed during pregnancy. A unilateral bone marrow biopsy should be performed for patients with B symptoms; clinical stage IIB to IV disease; and for patients with anemia, leukopenia, or thrombocytopenia. In addition, a thorough examination by an otolaryngologist should be performed for patients with stage IA or IIA disease with upper cervical lymph node involvement. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/33/29206?source=see_link&amp;anchor=H5#H5\">",
"     \"Initial evaluation and diagnosis of Hodgkin lymphoma in adults\", section on 'Bone marrow biopsy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If therapy is deferred until after delivery, a standard staging evaluation may be performed after delivery. In contrast, patients who receive treatment (eg, ABVD,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/3/4152?source=see_link\">",
"     vinblastine",
"    </a>",
"    ) during pregnancy cannot be accurately staged after delivery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/37/14935?source=see_link\">",
"     \"Staging and prognosis of Hodgkin lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     EFFECTS OF TREATMENT DURING PREGNANCY ON FETAL GROWTH AND DEVELOPMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both radiation therapy and chemotherapy are potential teratogens. The risk of fetal malformation or death is dependent upon the stage of fetal development, fetal susceptibility, the agent utilized, and the fetal dose of that agent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     First trimester",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first trimester is the most critical period for chemotherapeutic drug exposure, as implantation (weeks 1 to 2) and embryogenesis proceed (weeks 3 to 8). The major manifestations of drug toxicity at this time are spontaneous abortions during implantation and major morphological abnormalities during embryogenesis. Some structures, such as the limbs and palate, have limited \"windows\" of vulnerability during embryogenesis, while other organs, such as the central nervous system, may be affected throughout all phases of embryogenesis, fetal development, and growth.",
"   </p>",
"   <p>",
"    With chemotherapy, the placenta plays a pivotal role in drug transfer [",
"    <a class=\"abstract\" href=\"UTD.htm?12/31/12793/abstract/13\">",
"     13",
"    </a>",
"    ]. As such, chemotherapy administered inadvertently in the first two weeks of pregnancy (prior to the development of the placenta) will generally be less teratogenic [",
"    <a class=\"abstract\" href=\"UTD.htm?12/31/12793/abstract/14\">",
"     14",
"    </a>",
"    ]. In comparison, single agent and combination chemotherapy administered in the remainder of the first trimester results in a risk of congenital malformations of approximately 10 percent and 15 to 25 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?12/31/12793/abstract/14\">",
"     14",
"    </a>",
"    ]. The absolute risk is difficult to determine and varies with agent.",
"   </p>",
"   <p>",
"    The placental cells have a multidrug resistance phenotype [",
"    <a class=\"abstract\" href=\"UTD.htm?12/31/12793/abstract/15\">",
"     15",
"    </a>",
"    ], which may reduce or prevent transfer to the fetus of such natural products as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/3/4152?source=see_link\">",
"     vinblastine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    . However, case reports regarding the efficiency of placental transfer of doxorubicin are inconclusive. Fetal drug metabolism and excretion must also consider amniotic fluid recirculation (ie, fetal swallowing of the amniotic fluid). This feature helps to explain the marked teratogenicity of the folate antagonists, aminopterin and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    , when given at regular chemotherapeutic doses.",
"   </p>",
"   <p>",
"    Radiation exposure of the fetus during the first trimester is associated with teratogenesis and an increased risk of childhood malignancy (",
"    <a class=\"graphic graphic_table graphicRef57080 \" href=\"UTD.htm?31/7/31868\">",
"     table 3",
"    </a>",
"    ). The incidence of these effects depends upon the fetal dose of exposure, which in turn is dependent upon the radiation dose, radiation field size, and the distance between the radiation field and the fetus [",
"    <a class=\"abstract\" href=\"UTD.htm?12/31/12793/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H351935924\">",
"     'Radiation therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Second and third trimesters",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adverse effects of chemotherapy on the fetus are often more subtle during the second and third trimesters [",
"    <a class=\"abstract\" href=\"UTD.htm?12/31/12793/abstract/13,17\">",
"     13,17",
"    </a>",
"    ]. Among the possible toxic effects are low birth weight, intrauterine growth restriction, premature birth, stillborn fetus, impaired functional development, intellectual disability (mental retardation), and diminished learning capability. In one study, there was limited fetal exposure after the administration of ABVD to baboons in the second and third trimester of pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/31/12793/abstract/18\">",
"     18",
"    </a>",
"    ]. As described below, chemotherapy for HL has been administered successfully during the second and third trimesters with positive outcomes for both the mother and developing fetus. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Chemotherapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    With radiation therapy, increasing uterine fundal height affects total dose exposure from internal radiation scatter [",
"    <a class=\"abstract\" href=\"UTD.htm?12/31/12793/abstract/1\">",
"     1",
"    </a>",
"    ]. The closer the fetus is to the diaphragm, the greater the possible whole body fetal dose when the mother receives radiation above the diaphragm. However, this effect is potentially counteracted by the larger fetus being more developed and therefore less sensitive to radiation. Estimation of fetal radiation exposure during the three trimesters is available (",
"    <a class=\"graphic graphic_table graphicRef57080 \" href=\"UTD.htm?31/7/31868\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/31/12793/abstract/1,6,19-23\">",
"     1,6,19-23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Long-term outcome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The late manifestations of in utero exposure to antineoplastic agents may include impaired growth, diminished neurologic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    intellectual function, decreased gonadal and reproductive function, mutagenesis of germ-line tissue, and carcinogenesis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/31/12793/abstract/24\">",
"     24",
"    </a>",
"    ]. There are limited data that address the risks that may be involved. However, case series have demonstrated relatively good outcomes among children who were exposed to ABVD (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/3/4152?source=see_link\">",
"     vinblastine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/49/4887?source=see_link\">",
"     dacarbazine",
"    </a>",
"    ) during the second or third trimester [",
"    <a class=\"abstract\" href=\"UTD.htm?12/31/12793/abstract/7,25,26\">",
"     7,25,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One of the largest series assessed the status of 43 children exposed to chemotherapy during pregnancy; 14 of the pregnant mothers with HL received MOPP (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/57/40853?source=see_link\">",
"     mechlorethamine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/45/24279?source=see_link\">",
"     procarbazine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    )",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ABVD, five of them during the first trimester [",
"    <a class=\"abstract\" href=\"UTD.htm?12/31/12793/abstract/7\">",
"     7",
"    </a>",
"    ]. The children ranged in age from 3 to 19 years at the time of evaluation and were compared with a case control group of 25 children. In a comprehensive evaluation, all of the 43 children were within the normal range for routine blood work, lymphocyte function, immunoglobulins, cytogenetics, bone marrow aspirate and biopsy, school performance, neurologic testing, sexual development, and medical history. Further follow-up of the same cohort with expansion to 26 mothers with HL and a median follow-up of 18.7 years confirmed good health in the children and grandchildren [",
"    <a class=\"abstract\" href=\"UTD.htm?12/31/12793/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF HL DURING PREGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of HL during pregnancy requires a careful balance between maximizing the chance of cure and minimizing the potential harm to the developing fetus. While most pregnant women with HL diagnosed during pregnancy undergo therapy, case series have suggested that treatment can be safely deferred in selected women until fetal development and growth permits safe delivery. (See",
"    <a class=\"local\" href=\"#H351936082\">",
"     'Selection of patients for deferred therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The selection of initial treatment during pregnancy depends upon the trimester and the location and stage of disease. In general, therapy should be delayed until at least the second trimester, if possible, since the risks of treatment to the fetus are greatest during the first trimester. Some patients may be candidates for deferred therapy after the first trimester (ie, asymptomatic, stable, nonbulky, supradiaphragmatic disease). However, appropriate therapy should",
"    <strong>",
"     not",
"    </strong>",
"    be delayed past the first trimester in patients with symptomatic, bulky, subdiaphragmatic, or progressive HL. In addition, disease that seriously threatens the immediate well-being of the mother (eg, acute airway obstruction, spinal cord compression) requires emergent treatment at any time.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       First trimester",
"      </strong>",
"      &mdash; For most women with HL diagnosed during the first trimester of pregnancy, we recommend deferral of treatment until the second or third trimester, if possible. Patients with symptomatic or progressive HL that threatens the immediate well-being of the mother require treatment with chemotherapy. For patients who require a rapid tumor response, we suggest combination chemotherapy with ABVD (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"       bleomycin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/3/4152?source=see_link\">",
"       vinblastine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/49/4887?source=see_link\">",
"       dacarbazine",
"      </a>",
"      ). For patients who have progressive disease but do not require a rapid tumor response, we also suggest ABVD. Another option for this population is to administer single agent vinblastine with plans to administer combination chemotherapy after delivery. If chemotherapy is necessary within the first trimester, particularly early in the first trimester, termination of the pregnancy may also be discussed, as described below. (See",
"      <a class=\"local\" href=\"#H1951608\">",
"       'Elective termination of pregnancy'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      <strong>",
"       Second trimester",
"      </strong>",
"      &mdash; For most women with limited stage HL diagnosed during the second trimester of pregnancy, we suggest treatment with combination chemotherapy with ABVD. A subset of patients (ie, asymptomatic, stable, nonbulky, supradiaphragmatic disease) may choose close clinical monitoring with plans to administer chemotherapy after delivery. Radiation therapy may be used for local control of highly symptomatic disease above the diaphragm. &nbsp;",
"     </li>",
"     <li>",
"      <strong>",
"       Third trimester",
"      </strong>",
"      &mdash; For women with HL diagnosed during the third trimester of pregnancy, we suggest deferral of treatment until after delivery, if possible. This allows for a full staging evaluation and selection of appropriate therapy after delivery. However, patients with symptomatic or progressive HL that threatens the immediate well-being of the mother require treatment with chemotherapy. For such patients, we suggest combination chemotherapy with ABVD.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These treatment choices are described in more detail in the following sections. Despite the increasing availability of guidelines for the treatment of HL, there must remain room for individualization of treatment. In particular, patient preference must be considered with different treatment options, some of which result in a higher recurrence risk at the gain of less toxic initial treatment.",
"   </p>",
"   <p>",
"    The issue of pregnancy termination varies with the clinical setting. It is rarely medically indicated with newly diagnosed HL, since even combination chemotherapy (ie, ABVD) has been successfully administered in the first trimester. Similarly, relapse that occurs after radiotherapy alone may be satisfactorily managed with chemotherapy. In contrast, pregnancy termination is often indicated with relapsed HL following combination chemotherapy, since high-dose chemotherapy with stem cell support (autologous hematopoietic cell transplantation) is usually the preferred therapy. (See",
"    <a class=\"local\" href=\"#H1951608\">",
"     'Elective termination of pregnancy'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/17/37145?source=see_link&amp;anchor=H11#H11\">",
"     \"Treatment of relapse of classical Hodgkin lymphoma after initial chemotherapy\", section on 'High dose chemotherapy and transplantation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H351936082\">",
"    <span class=\"h2\">",
"     Selection of patients for deferred therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;If possible, therapy for HL should be delayed until at least the second trimester since the risks of treatment to the fetus are greatest during the first trimester. Some patients may be candidates for deferred therapy after the first trimester. This approach is preferred by some clinicians due to the potential teratogenicity of treatment and the indolent clinical nature of many cases of HL. Potential candidates for deferral of therapy after the first trimester include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      \"Limited\" clinical stage IA or IIA HL presenting during the late second and third trimester (",
"      <a class=\"graphic graphic_table graphicRef73699 \" href=\"UTD.htm?36/59/37819\">",
"       table 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Stable \"non-urgent\" HL diagnosed after 20 weeks gestation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There have been no prospective trials that have compared deferred therapy with immediate treatment in this setting. It is unknown whether deferral of therapy has an impact on long-term survival rates. Data regarding the safety and efficacy of this approach come from two case series:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Stanford group described five women in whom therapy was delayed: three with clinical stage IIA HL, all of whom were in continuous complete remission following successful therapy postdelivery; and two with infradiaphragmatic disease, both of whom died of HL despite therapy postdelivery [",
"      <a class=\"abstract\" href=\"UTD.htm?12/31/12793/abstract/4,5\">",
"       4,5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A Canadian group used a minimalist approach to manage 17 women with HL during pregnancy [",
"      <a class=\"abstract\" href=\"UTD.htm?12/31/12793/abstract/27\">",
"       27",
"      </a>",
"      ]. Eleven did not require therapy until after delivery and six were managed with single agent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/3/4152?source=see_link\">",
"       vinblastine",
"      </a>",
"      during pregnancy. All 17 delivered healthy babies who had a median age of 15 years at last follow-up. Of the 17 women, 13 were alive and in complete remission while four had died (two from HL, one from acute myeloid leukemia, and one from retroperitoneal sarcoma).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The decision to treat or monitor the pregnant woman with HL must be individualized. Deferral of immediate therapy allows for accurate staging of disease after delivery and treatment based upon disease stage; however, it is unknown whether deferral of therapy impairs disease control and affects survival. If deferral is selected, patients must be monitored closely for progression. Disease that is easily assessable with physical examination aids in this monitoring. Serial abdominal ultrasound can also monitor for the development or progression of subdiaphragmatic disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Combination chemotherapy offers potentially curative treatment of HL. However, because of concern regarding possible immediate and delayed side effects to the fetus and delivered child, conventional combination chemotherapy has had limited study in the pregnant patient. For most women with HL diagnosed during the first trimester of pregnancy, we recommend deferral of treatment until the second or third trimester, if possible.",
"   </p>",
"   <p>",
"    In a comprehensive review of antineoplastic agents and pregnancy, the incidence of fetal malformations was approximately 15 percent after exposure during the first trimester [",
"    <a class=\"abstract\" href=\"UTD.htm?12/31/12793/abstract/28\">",
"     28",
"    </a>",
"    ]. The risk was greatest with alkylating agents and antimetabolites, while",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/3/4152?source=see_link\">",
"     vinblastine",
"    </a>",
"    was associated with the lowest risk (one abnormality among 14 patients treated in the first trimester). Similar data were found in another series [",
"    <a class=\"abstract\" href=\"UTD.htm?12/31/12793/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    During the second and third trimesters, chemotherapy was associated with a low risk of fetal malformation (1.3 percent of 150 exposed patients) that was probably not significantly different from the normal population (3.1 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/31/12793/abstract/28\">",
"     28",
"    </a>",
"    ]. However, the relative lack of anomalies should not be interpreted as fetal safety, since delayed effects remain a significant concern. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Long-term outcome'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Specific regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ideal chemotherapy regimen to use for HL during pregnancy is unknown. The main options include combination chemotherapy with ABVD (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/3/4152?source=see_link\">",
"     vinblastine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/49/4887?source=see_link\">",
"     dacarbazine",
"    </a>",
"    (",
"    <a class=\"graphic graphic_table graphicRef68131 \" href=\"UTD.htm?0/59/958\">",
"     table 4",
"    </a>",
"    )) or single agent vinblastine. MOPP (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/57/40853?source=see_link\">",
"     mechlorethamine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/45/24279?source=see_link\">",
"     procarbazine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    ) does not appear to be as safe as ABVD and is no longer used for the initial treatment of HL [",
"    <a class=\"abstract\" href=\"UTD.htm?12/31/12793/abstract/28\">",
"     28",
"    </a>",
"    ]. There are no data regarding the use of BEACOPP (bleomycin,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    , doxorubicin,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , vincristine, procarbazine, and prednisone) or Stanford V (doxorubicin, vinblastine, mechlorethamine, vincristine, bleomycin, etoposide, and prednisone) during pregnancy.",
"   </p>",
"   <p>",
"    Data regarding the use of chemotherapy for HL during pregnancy come largely from small case series. A 2008 comprehensive literature review published by the American Society of Hematology, summarized data from case series and reported that there was very limited information [",
"    <a class=\"abstract\" href=\"UTD.htm?12/31/12793/abstract/29\">",
"     29",
"    </a>",
"    ]. Good fetal outcomes were reported following either standard ABVD or single agent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/3/4152?source=see_link\">",
"     vinblastine",
"    </a>",
"    . Of these, ABVD was generally preferred because it is a standard of care for patients with HL that appears to have limited fetal toxicity when administered during pregnancy. However, some clinicians may choose single agent vinblastine due to lower rates of expected fetal toxicity. In general, pregnant women receive similar body surface area based chemotherapy doses as nonpregnant women, which are adjusted with continued weight gains. (See",
"    <a class=\"local\" href=\"#H1951804\">",
"     'Effect of pregnancy on drug pharmacokinetics'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    If chemotherapy (either ABVD or single agent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/3/4152?source=see_link\">",
"     vinblastine",
"    </a>",
"    ) is administered during pregnancy, staging after delivery cannot be used to guide initial treatment. Instead, patients should be treated after delivery as if they had advanced stage HL at diagnosis (eg, completion of four to six cycles of ABVD). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/54/39786?source=see_link&amp;anchor=H7#H7\">",
"     \"Initial treatment of advanced (stage III-IV) classical Hodgkin lymphoma\", section on 'ABVD chemotherapy'",
"    </a>",
"    .) &nbsp; &nbsp; &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1951594\">",
"    <span class=\"h3\">",
"     Antiemetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antiemetics, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/20/15688?source=see_link\">",
"     promethazine",
"    </a>",
"    , selective serotonin (5-HT) antagonists, neurokinin 1 (NK1) antagonists, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/19/9527?source=see_link\">",
"     droperidol",
"    </a>",
"    combined with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/2/33824?source=see_link\">",
"     diphenhydramine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    are used to treat severe nausea and vomiting in pregnant women and are generally considered safe. However, long-term dexamethasone therapy should be avoided, if possible, because of potential maternal and fetal risks. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/20/29002?source=see_link\">",
"     \"Treatment and outcome of nausea and vomiting of pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1951804\">",
"    <span class=\"h3\">",
"     Effect of pregnancy on drug pharmacokinetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, pregnant women receive similar body surface area based chemotherapy doses as nonpregnant women, which are adjusted with continued weight gains [",
"    <a class=\"abstract\" href=\"UTD.htm?12/31/12793/abstract/30\">",
"     30",
"    </a>",
"    ]. Little information is available regarding the pharmacokinetics of individual cytotoxic agents in the pregnant patient. Alterations in drug distribution are expected due to the physiologic changes that occur with pregnancy, which include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Increases in blood volume and renal and hepatic clearance might be expected to reduce active drug concentrations. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/32/24072?source=see_link\">",
"       \"Renal and urinary tract physiology in normal pregnancy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Diminished gastric motility may affect the absorption of orally administered drugs.",
"     </li>",
"     <li>",
"      Plasma albumin decreases in pregnancy, increasing the amount of unbound active drug; however, this effect is counterbalanced by high levels of estrogen, which increases other plasma proteins.",
"     </li>",
"     <li>",
"      The \"third space\" of the amniotic sac.",
"     </li>",
"     <li>",
"      The multidrug resistance p-glycoprotein has been detected in fetal tissues and in the gravid endometrium and may offer some degree of protection to the fetus [",
"      <a class=\"abstract\" href=\"UTD.htm?12/31/12793/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is unclear how these physiologic changes affect active drug concentrations and their resulting efficacy and toxicity. The deleterious effects of drug exposures on the fetus are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/7/19574?source=see_link\">",
"     \"Principles of teratology\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H351935924\">",
"    <span class=\"h2\">",
"     Radiation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiation therapy can offer local disease control, but is associated with teratogenesis and an increased risk of childhood malignancy. &nbsp;Many series have documented the effectiveness of radiation therapy for treatment of HL during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/31/12793/abstract/1,3,4,6\">",
"     1,3,4,6",
"    </a>",
"    ]. Several principles should be followed when this approach is chosen:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Irradiation should be delayed until the second or third trimester",
"     </li>",
"     <li>",
"      The whole body fetal dose should be limited to 0.10 Gy or less",
"     </li>",
"     <li>",
"      The aim is for local response and disease control until delivery",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    One series provided a complete analysis of 16 pregnant women (2 stage IA and 14 stage IIA) with HL who were treated at MD Anderson Cancer Center [",
"    <a class=\"abstract\" href=\"UTD.htm?12/31/12793/abstract/1\">",
"     1",
"    </a>",
"    ]. Radiation therapy was administered as involved field to the neck (35 Gy) in two, extended field to",
"    <span class=\"nowrap\">",
"     neck/mediastinum",
"    </span>",
"    (40 Gy) in three, and full mantle irradiation (40 Gy) in the others. Uterine shielding was maximized by four to five half-value layers of lead. The estimated dose to the fetus was 0.011 to 0.055 Gy with 6 MV photons and 0.10 to 0.14 Gy for cobalt 60. Following delivery, 10 patients had lymphangiography and five underwent staging laparotomy (two with positive findings). Eight patients subsequently had additional radiation therapy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    chemotherapy. All offspring were reported to be physically and mentally normal and the 10-year survival of the patients was 83 percent.",
"   </p>",
"   <p>",
"    Similar findings were noted in a review of 23 patients who received supradiaphragmatic radiation therapy (five in the first trimester) with apparently no harm to the fetus noted [",
"    <a class=\"abstract\" href=\"UTD.htm?12/31/12793/abstract/6\">",
"     6",
"    </a>",
"    ]. Seventeen of these patients (74 percent) had no evidence of HL at the time of the report.",
"   </p>",
"   <p>",
"    Fetal outcome following radiotherapy is dependent upon gestational age when radiation is given, whole body fetal dose, and maternal health (",
"    <a class=\"graphic graphic_table graphicRef57080 \" href=\"UTD.htm?31/7/31868\">",
"     table 3",
"    </a>",
"    ). A higher frequency of spontaneous abortion and congenital anomaly has not been convincingly demonstrated. Among the series described above, 16 pregnancies resulted in 16 full-term infants [",
"    <a class=\"abstract\" href=\"UTD.htm?12/31/12793/abstract/1\">",
"     1",
"    </a>",
"    ], and 10 pregnancies resulted in one spontaneous abortion in a patient irradiated during the first trimester, three therapeutic abortions, and six normal infants [",
"    <a class=\"abstract\" href=\"UTD.htm?12/31/12793/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Radiation fields should be designed with measures that will minimize the fetal dose by maximizing the distance between the inferior border of the field and the uterus. Protection of the uterus during radiotherapy should be with 10 HVL shielding. Calculation of the maximal dose to the fetus should be performed prior to treatment and the dose to the fetus should be monitored during treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?12/31/12793/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1951608\">",
"    <span class=\"h2\">",
"     Elective termination of pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The decision to continue or terminate the pregnancy should be individualized and made by a fully informed woman in conjunction with her clinician. Elective termination of the pregnancy is rarely medically indicated with newly diagnosed HL, since even combination chemotherapy has been successfully administered in the first trimester. In contrast, pregnancy termination is often indicated with relapsed HL following combination chemotherapy, since high-dose chemotherapy with stem cell support (autologous hematopoietic cell transplantation) is usually the preferred therapy.",
"   </p>",
"   <p>",
"    In addition to the usual reasons for pregnancy termination, some factors that should be considered in women with HL during pregnancy include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Whether she is willing to assume a possible risk of fetal toxicity or complications from HL treatment during pregnancy",
"     </li>",
"     <li>",
"      Her prognosis and ability to care for her offspring",
"     </li>",
"     <li>",
"      The effect of HL treatment on future fertility (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/50/7977?source=see_link\">",
"       \"Overview of fertility and pregnancy in cancer survivors\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     DELIVERY OF THE INFANT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The timing of delivery of the infant must be a joint decision between the obstetrician, hematologist-oncologist, and the patient. Whenever possible, the fetus should be carried to term without compromising the health of the mother or infant. If not, the fetus should be delivered after demonstration of fetal pulmonary maturity and at 34 or more weeks of gestation at which time morbidity of prematurity is relatively low. Cesarean section is not necessary unless obstetrically indicated, and staging laparotomy, performed in conjunction with delivery, is not warranted. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/11/14520?source=see_link\">",
"     \"Incidence and mortality of the premature infant\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The importance of avoiding iatrogenic preterm delivery was illustrated in a multicenter observational study of 70 children who were exposed to maternal cancer staging and treatment during gestation and followed for a median of 22 months (range 17 to 212 months) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/31/12793/abstract/32\">",
"     32",
"    </a>",
"    ]. Exposure to chemotherapy during gestation was not associated with increased central nervous system, cardiac, or auditory impairment. However, cognitive development scores were lower for children born preterm, with intelligence quotient increasing by an average of 11.6 points for each additional month of gestation.",
"   </p>",
"   <p>",
"    If treatment has been administered prior to delivery, the blood counts of both the mother and the infant should be monitored for the development of cytopenia [",
"    <a class=\"abstract\" href=\"UTD.htm?12/31/12793/abstract/7,25\">",
"     7,25",
"    </a>",
"    ]. If possible, no potentially myelosuppressive therapy should be administered within three weeks of delivery. The timing of chemotherapy may also become important prior to delivery since the neonate has a limited ability to metabolize and excrete drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?12/31/12793/abstract/33\">",
"     33",
"    </a>",
"    ]. Thus, transient cytopenias have been described in some infants of mothers with lymphoma or leukemia who received chemotherapy within 30 days of delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?12/31/12793/abstract/7,25\">",
"     7,25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     MANAGEMENT AFTER DELIVERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who have deferred treatment until after delivery can undergo a standard staging evaluation and proceed with treatment as in the nonpregnant patient. Imaging studies performed after chemotherapy or radiation therapy will not provide accurate data regarding the initial stage of disease. As such, patients who receive treatment should proceed with further treatment as if they initially had advanced stage disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/37/14935?source=see_link\">",
"     \"Staging and prognosis of Hodgkin lymphoma\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    It is recommended that breastfeeding be discontinued once staging and therapy are begun, since contrast and nuclear medicine imaging agents, chemotherapy, and ancillary supportive medications may concentrate in breast milk. Many cytotoxic drugs, especially the alkylating agents, are excreted in breast milk [",
"    <a class=\"abstract\" href=\"UTD.htm?12/31/12793/abstract/34\">",
"     34",
"    </a>",
"    ]. Neonatal neutropenia has been reported in an infant breastfed during maternal treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?12/31/12793/abstract/35\">",
"     35",
"    </a>",
"    ]. As a general rule, breastfeeding should be avoided in women while receiving chemotherapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/1/32794?source=see_link\">",
"     \"Principles of medication use during lactation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Due to safety concerns, most radiologists suggest that patients avoid contact with infants for 12 hours following a PET scan.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H96544541\">",
"    <span class=\"h1\">",
"     INFLUENCE OF PREGNANCY ON THE COURSE OF HL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnancy appears to have",
"    <strong>",
"     no",
"    </strong>",
"    significant effect on the course of HL [",
"    <a class=\"abstract\" href=\"UTD.htm?12/31/12793/abstract/1-7,36,37\">",
"     1-7,36,37",
"    </a>",
"    ]. One report, for example, evaluated 347 women of childbearing age with HL who were seen at the Memorial Sloan-Kettering Cancer Center from 1910 until 1960; 112 pregnancies occurred in 84 of these women [",
"    <a class=\"abstract\" href=\"UTD.htm?12/31/12793/abstract/37\">",
"     37",
"    </a>",
"    ]. The survival curve and the median survival time of 90 months were similar in both groups. Survival statistics were similar for patients who had their pregnancy aborted and for patients whose pregnancy was allowed to continue.",
"   </p>",
"   <p>",
"    Subsequent studies have reported similar results. In a study published in 1992, cause-specific survival in 33 pregnant patients was compared with 67 case-matched controls. Approximately 70 percent of both groups were alive at 25 years, with no significant effect of age or stage at diagnosis on outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?12/31/12793/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23221710\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The peak incidence of Hodgkin lymphoma (HL) coincides with female reproductive age and a subset of patients will be found to be pregnant at the time of HL diagnosis. All women of childbearing age receiving therapy for HL should have pregnancy testing prior to treatment and should be counseled regarding birth control measures during therapy.",
"     </li>",
"     <li>",
"      Women diagnosed with HL during pregnancy present in a similar fashion to those who are not pregnant, usually with painless lymphadenopathy or symptoms related to a mediastinal mass. The diagnosis is confirmed by biopsy, typically of a peripheral lymph node. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical presentation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H96544367\">",
"       'Diagnosis'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      Once the diagnosis of HL is confirmed, staging studies should include a single",
"      <span class=\"nowrap\">",
"       posterior/anterior",
"      </span>",
"      view chest x-ray with adequate abdominal shielding, ultrasound or magnetic resonance imaging of the abdomen (and chest if abnormalities are seen on the chest x-ray), complete blood count, erythrocyte sedimentation rate, serum creatinine concentration, serum liver enzymes, and bone marrow biopsy (",
"      <a class=\"graphic graphic_table graphicRef81526 \" href=\"UTD.htm?3/47/3836\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Staging during pregnancy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/37/14935?source=see_link\">",
"       \"Staging and prognosis of Hodgkin lymphoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The selection of initial treatment during pregnancy depends upon the trimester and the location and stage of disease. In general, therapy should be delayed until at least the second trimester. Some patients may be candidates for deferred therapy after the first trimester. However, disease that seriously threatens the immediate well-being of the mother (eg, acute airway obstruction, spinal cord compression) requires emergent treatment at any time. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Management of HL during pregnancy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <strong>",
"       First trimester",
"      </strong>",
"      &mdash; For most women with HL diagnosed during the first trimester of pregnancy, we recommend deferral of treatment until the second or third trimester, if possible (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). Patients with symptomatic or progressive HL that threatens the immediate well-being of the mother require treatment with chemotherapy. For these patients, we suggest combination chemotherapy with ABVD (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"       bleomycin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/3/4152?source=see_link\">",
"       vinblastine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/49/4887?source=see_link\">",
"       dacarbazine",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Chemotherapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Second trimester",
"      </strong>",
"      &mdash; For most women with limited stage HL diagnosed during the second trimester of pregnancy, we suggest treatment with combination chemotherapy (ie, ABVD) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). A subset of patients (ie, asymptomatic, stable, nonbulky, supradiaphragmatic disease) may choose close clinical monitoring with plans to administer chemotherapy after delivery. Radiation therapy may be used for local control of highly symptomatic disease above the diaphragm. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Specific regimens'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H351936082\">",
"       'Selection of patients for deferred therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Third trimester",
"      </strong>",
"      &mdash; For women with HL diagnosed during the third trimester of pregnancy, we suggest deferral of treatment until after delivery, if possible (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). This allows for a full staging evaluation and selection of appropriate therapy after delivery. However, patients with symptomatic or progressive HL that threatens the immediate well-being of the mother require treatment with chemotherapy. For such patients, we suggest combination chemotherapy with ABVD. (See",
"      <a class=\"local\" href=\"#H351936082\">",
"       'Selection of patients for deferred therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Adverse effects on the fetus during the second and third trimesters include low birth weight, intrauterine growth restriction, premature birth, stillborn fetus, impaired functional development, intellectual disability (mental retardation), and diminished learning capability. The late manifestations of in utero exposure to antineoplastic agents may include impaired growth, diminished neurologic",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      intellectual function, decreased gonadal and reproductive function, mutagenesis of germ-line tissue, and carcinogenesis. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Second and third trimesters'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Long-term outcome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All pregnant women with HL should be managed by a high-risk obstetrician. Early delivery may not be required if the patient has received, or is receiving, adequate therapy. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Delivery of the infant'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The issue of pregnancy termination varies with the clinical setting. It is rarely medically indicated with newly diagnosed HL, since even combination chemotherapy (eg, ABVD) has been successfully administered in the first trimester. In contrast, pregnancy termination is often indicated with relapsed HL following combination chemotherapy, since high-dose chemoradiotherapy with stem cell support (autologous hematopoietic cell transplantation) is usually the preferred therapy. (See",
"      <a class=\"local\" href=\"#H1951608\">",
"       'Elective termination of pregnancy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12793/abstract/1\">",
"      Woo SY, Fuller LM, Cundiff JH, et al. Radiotherapy during pregnancy for clinical stages IA-IIA Hodgkin's disease. Int J Radiat Oncol Biol Phys 1992; 23:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12793/abstract/2\">",
"      STEWART HL Jr, MONTO RW. Hodgkin's disease and pregnancy. Am J Obstet Gynecol 1952; 63:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12793/abstract/3\">",
"      Lishner M, Zemlickis D, Degendorfer P, et al. Maternal and foetal outcome following Hodgkin's disease in pregnancy. Br J Cancer 1992; 65:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12793/abstract/4\">",
"      Jacobs C, Donaldson SS, Rosenberg SA, Kaplan HS. Management of the pregnant patient with Hodgkin's disease. Ann Intern Med 1981; 95:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12793/abstract/5\">",
"      Gelb AB, van de Rijn M, Warnke RA, Kamel OW. Pregnancy-associated lymphomas. A clinicopathologic study. Cancer 1996; 78:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12793/abstract/6\">",
"      Yahalom J. Treatment options for Hodgkin's disease during pregnancy. Leuk Lymphoma 1990; 2:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12793/abstract/7\">",
"      Avil&eacute;s A, D&iacute;az-Maqueo JC, Talavera A, et al. Growth and development of children of mothers treated with chemotherapy during pregnancy: current status of 43 children. Am J Hematol 1991; 36:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12793/abstract/8\">",
"      Cohen-Kerem R, Railton C, Oren D, et al. Pregnancy outcome following non-obstetric surgical intervention. Am J Surg 2005; 190:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12793/abstract/9\">",
"      Levine D, Barnes PD, Edelman RR. Obstetric MR imaging. Radiology 1999; 211:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12793/abstract/10\">",
"      Pelsang RE. Diagnostic imaging modalities during pregnancy. Obstet Gynecol Clin North Am 1998; 25:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12793/abstract/11\">",
"      Kanal E, Barkovich AJ, Bell C, et al. ACR guidance document for safe MR practices: 2007. AJR Am J Roentgenol 2007; 188:1447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12793/abstract/12\">",
"      Zanotti-Fregonara P, Jan S, Taieb D, et al. Absorbed 18F-FDG dose to the fetus during early pregnancy. J Nucl Med 2010; 51:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12793/abstract/13\">",
"      Brewer M, Kueck A, Runowicz CD. Chemotherapy in pregnancy. Clin Obstet Gynecol 2011; 54:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12793/abstract/14\">",
"      Rizack T, Mega A, Legare R, Castillo J. Management of hematological malignancies during pregnancy. Am J Hematol 2009; 84:830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12793/abstract/15\">",
"      Cordon-Cardo C, O'Brien JP, Casals D, et al. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci U S A 1989; 86:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12793/abstract/16\">",
"      Martin DD. Review of radiation therapy in the pregnant cancer patient. Clin Obstet Gynecol 2011; 54:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12793/abstract/17\">",
"      Anatolian Medical Oncology Society Group, Ustaalioglu BB, Gumus M, et al. Malignancies diagnosed during pregnancy and treated with chemotherapy or other modalities (review of 27 cases): multicenter experiences. Int J Gynecol Cancer 2010; 20:698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12793/abstract/18\">",
"      Van Calsteren K, Verbesselt R, Beijnen J, et al. Transplacental transfer of anthracyclines, vinblastine, and 4-hydroxy-cyclophosphamide in a baboon model. Gynecol Oncol 2010; 119:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12793/abstract/19\">",
"      Zucali R, Marchesini R, De Palo G. Abdominal dosimetry for supradiaphragmatic irradiation of Hodgkin's disease in pregnancy. Experimental data and clinical considerations. Tumori 1981; 67:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12793/abstract/20\">",
"      Covington EE, Baker AS. Dosimetry of scattered radiation to the fetus. JAMA 1969; 209:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12793/abstract/21\">",
"      Wong PS, Rosemark PJ, Wexler MC, et al. Doses to organs at risk from mantle field radiation therapy using 10 MV x-rays. Mt Sinai J Med 1985; 52:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12793/abstract/22\">",
"      Sharma SC, Williamson JF, Khan FM, Lee CK. Measurement and calculation of ovary and fetus dose in extended field radiotherapy for 10 MV x rays. Int J Radiat Oncol Biol Phys 1981; 7:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12793/abstract/23\">",
"      Mazonakis M, Varveris H, Fasoulaki M, Damilakis J. Radiotherapy of Hodgkin's disease in early pregnancy: embryo dose measurements. Radiother Oncol 2003; 66:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12793/abstract/24\">",
"      Garber JE. Long-term follow-up of children exposed in utero to antineoplastic agents. Semin Oncol 1989; 16:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12793/abstract/25\">",
"      Reynoso EE, Shepherd FA, Messner HA, et al. Acute leukemia during pregnancy: the Toronto Leukemia Study Group experience with long-term follow-up of children exposed in utero to chemotherapeutic agents. J Clin Oncol 1987; 5:1098.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12793/abstract/26\">",
"      Avil&eacute;s A, Neri N. Hematological malignancies and pregnancy: a final report of 84 children who received chemotherapy in utero. Clin Lymphoma 2001; 2:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12793/abstract/27\">",
"      Connors JM. Challenging problems: coincident pregnancy, HIV infection, and older age. Hematology Am Soc Hematol Educ Program 2008; :334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12793/abstract/28\">",
"      Doll DC, Ringenberg QS, Yarbro JW. Antineoplastic agents and pregnancy. Semin Oncol 1989; 16:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12793/abstract/29\">",
"      Bachanova V, Connors JM. How is Hodgkin lymphoma in pregnancy best treated? ASH evidence-based review 2008. Hematology Am Soc Hematol Educ Program 2008; :33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12793/abstract/30\">",
"      Cardonick E, Iacobucci A. Use of chemotherapy during human pregnancy. Lancet Oncol 2004; 5:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12793/abstract/31\">",
"      Kal HB, Struikmans H. Radiotherapy during pregnancy: fact and fiction. Lancet Oncol 2005; 6:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12793/abstract/32\">",
"      Amant F, Van Calsteren K, Halaska MJ, et al. Long-term cognitive and cardiac outcomes after prenatal exposure to chemotherapy in children aged 18 months or older: an observational study. Lancet Oncol 2012; 13:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12793/abstract/33\">",
"      Barnicle MM. Chemotherapy and pregnancy. Semin Oncol Nurs 1992; 8:124.",
"     </a>",
"    </li>",
"    <li>",
"     Briggs GG, Freeman RK, Yaffe SJ. Drugs in Pregnancy and Lactation, 8th ed, Lippincott Williams &amp; Wilkins, Philadelphia, PA 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12793/abstract/35\">",
"      Durodola JI. Administration of cyclophosphamide during late pregnancy and early lactation: a case report. J Natl Med Assoc 1979; 71:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12793/abstract/36\">",
"      HENNESSY JP, ROTTINO A. HODGKIN'S DISEASE IN PREGNANCY. Am J Obstet Gynecol 1963; 87:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12793/abstract/37\">",
"      BARRY RM, DIAMOND HD, CRAVER LF. Influence of pregnancy on the course of Hodgkin's disease. Am J Obstet Gynecol 1962; 84:445.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4692 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.234.146.186-BFC6E11EC2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_31_12793=[""].join("\n");
var outline_f12_31_12793=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23221710\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H96544367\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      STAGING DURING PREGNANCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      EFFECTS OF TREATMENT DURING PREGNANCY ON FETAL GROWTH AND DEVELOPMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      First trimester",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Second and third trimesters",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Long-term outcome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      MANAGEMENT OF HL DURING PREGNANCY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H351936082\">",
"      Selection of patients for deferred therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Specific regimens",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1951594\">",
"      - Antiemetics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1951804\">",
"      - Effect of pregnancy on drug pharmacokinetics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H351935924\">",
"      Radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1951608\">",
"      Elective termination of pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      DELIVERY OF THE INFANT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      MANAGEMENT AFTER DELIVERY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H96544541\">",
"      INFLUENCE OF PREGNANCY ON THE COURSE OF HL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23221710\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/4692\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4692|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/59/37819\" title=\"table 1\">",
"      Ann Arbor system in lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/47/3836\" title=\"table 2\">",
"      Staging of HL in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?31/7/31868\" title=\"table 3\">",
"      Radiation dose to fetus in HL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/59/958\" title=\"table 4\">",
"      ABVD chemotherapy for Hodgkin lymphoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/35/568?source=related_link\">",
"      Clinical presentation and patterns of disease distribution in classical Hodgkin lymphoma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/29/28120?source=related_link\">",
"      Diagnostic imaging procedures during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/13/15578?source=related_link\">",
"      Epidemiology, pathologic features, and diagnosis of classical Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/11/14520?source=related_link\">",
"      Incidence and mortality of the premature infant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/33/29206?source=related_link\">",
"      Initial evaluation and diagnosis of Hodgkin lymphoma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/54/39786?source=related_link\">",
"      Initial treatment of advanced (stage III-IV) classical Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/50/7977?source=related_link\">",
"      Overview of fertility and pregnancy in cancer survivors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/12/13512?source=related_link\">",
"      Overview of the treatment of classical Hodgkin lymphoma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/1/32794?source=related_link\">",
"      Principles of medication use during lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/7/19574?source=related_link\">",
"      Principles of teratology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/32/24072?source=related_link\">",
"      Renal and urinary tract physiology in normal pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/37/14935?source=related_link\">",
"      Staging and prognosis of Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/56/38793?source=related_link\">",
"      Thrombocytopenia in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/20/29002?source=related_link\">",
"      Treatment and outcome of nausea and vomiting of pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/17/37145?source=related_link\">",
"      Treatment of relapse of classical Hodgkin lymphoma after initial chemotherapy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_31_12794="Bleomycin-induced lung injury";
var content_f12_31_12794=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"7\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Bleomycin-induced lung injury",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/31/12794/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/31/12794/contributors\">",
"     Timothy D Gilligan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/31/12794/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/31/12794/contributors\">",
"     Kevin R Flaherty, MD, MS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/31/12794/contributors\">",
"     James R Jett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/31/12794/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/31/12794/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/31/12794/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/31/12794/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 10, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     Bleomycin",
"    </a>",
"    is an antitumor antibiotic that was isolated from a strain of Streptomyces verticillus in 1966 [",
"    <a class=\"abstract\" href=\"UTD.htm?12/31/12794/abstract/1\">",
"     1",
"    </a>",
"    ]. It has been used successfully to treat a variety of malignancies, including squamous cell carcinoma of the head and neck, cervix, and esophagus; germ cell tumors; and both Hodgkin and non-Hodgkin lymphoma.",
"   </p>",
"   <p>",
"    The major limitation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    therapy is the potential for life-threatening interstitial pulmonary fibrosis (also called fibrosing alveolitis) in up to 10 percent of patients receiving the drug [",
"    <a class=\"abstract\" href=\"UTD.htm?12/31/12794/abstract/2-5\">",
"     2-5",
"    </a>",
"    ]. Other, less common forms of lung injury include organizing pneumonia and hypersensitivity pneumonitis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/31/12794/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pathogenesis and clinical aspects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    -induced lung injury will be reviewed here. Potential drug interactions that may modify the course of bleomycin-induced lung injury and the therapeutic options available for management will also be discussed. A general approach to immunocompromised patients with respiratory symptoms and the evaluation of interstitial lung disease are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/51/25402?source=see_link\">",
"     \"Approach to the immunocompromised patient with fever and pulmonary infiltrates\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PHARMACOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The antineoplastic effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    is unique among anticancer agents, and is thought to involve the production of single- and double-strand breaks in DNA (scission) by a complex of bleomycin, ferrous ions, and molecular oxygen&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?12/31/12794/abstract/2,6,7\">",
"     2,6,7",
"    </a>",
"    ]. Bleomycin binds to DNA by intercalation of the bithiazole moiety between base pairs of DNA and by electrostatic interactions of the terminal amines. The reduction of molecular oxygen by ferrous ions chelated by bleomycin leads to hydrogen subtraction from the C3 and C4 carbons of deoxyribose, resulting in cleavage of the C3-C4 bond and liberation of a base with a DNA strand break [",
"    <a class=\"abstract\" href=\"UTD.htm?12/31/12794/abstract/6\">",
"     6",
"    </a>",
"    ]. Bleomycin is inactivated in vivo by the enzyme bleomycin hydrolase, a cytosolic aminopeptidase that has lower activity in the skin and lungs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mechanism of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    -induced lung injury is not entirely clear, but likely includes components of oxidative damage, relative deficiency of the deactivating enzyme bleomycin hydrolase, genetic susceptibility, and elaboration of inflammatory cytokines.",
"   </p>",
"   <p>",
"    Oxidative damage to the lung appears important in the pathophysiology of lung injury, and antioxidants may ameliorate the process [",
"    <a class=\"abstract\" href=\"UTD.htm?12/31/12794/abstract/4,8\">",
"     4,8",
"    </a>",
"    ]. Depletion of iron with chelators also reduces the toxicity of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    both in vitro and in vivo, probably secondary to decreased production of free radicals [",
"    <a class=\"abstract\" href=\"UTD.htm?12/31/12794/abstract/4,9,10\">",
"     4,9,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     Bleomycin",
"    </a>",
"    hydrolase, an enzyme that degrades bleomycin, is active in all tissues with the exception of the skin and the lung, which may account for the specific toxicity of the drug to these organs [",
"    <a class=\"abstract\" href=\"UTD.htm?12/31/12794/abstract/2,6,11\">",
"     2,6,11",
"    </a>",
"    ]. The acute pulmonary toxicity of bleomycin has been attributed to DNA strand scission with resulting chromosomal injury [",
"    <a class=\"abstract\" href=\"UTD.htm?12/31/12794/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Animal models confirm that more chronic bleomycin injury occurs predominantly in the lung, which has very low levels of bleomycin hydrolase activity [",
"    <a class=\"abstract\" href=\"UTD.htm?12/31/12794/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The influence of genetic factors in the development of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    -induced lung injury is suggested by the large variation in bleomycin sensitivity among treated patients, and by data showing that the development of bleomycin-induced lung injury in rodents is strain-specific. Murine strains are recognized as bleomycin-sensitive",
"    <span class=\"nowrap\">",
"     (C57BL/6)",
"    </span>",
"    or bleomycin-resistant",
"    <span class=\"nowrap\">",
"     (BALB/c)",
"    </span>",
"    according to their ability to develop bleomycin-induced pulmonary fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/31/12794/abstract/12-14\">",
"     12-14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies investigating the varying susceptibility of mouse strains to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    reveal that a bleomycin-resistant strain",
"    <span class=\"nowrap\">",
"     (BALB/c)",
"    </span>",
"    has much greater bleomycin hydrolase activity compared to a bleomycin-sensitive strain. This effect is drug-specific, since",
"    <span class=\"nowrap\">",
"     BALB/c",
"    </span>",
"    mice are more sensitive to cyclophosphamide-induced lung injury than are some bleomycin-sensitive strains [",
"    <a class=\"abstract\" href=\"UTD.htm?12/31/12794/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The chronic fibrotic response to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    -induced injury is associated with an acquired loss of bleomycin hydrolase activity [",
"    <a class=\"abstract\" href=\"UTD.htm?12/31/12794/abstract/16\">",
"     16",
"    </a>",
"    ] and is mediated by an immunologic mechanism, characterized by the migration of activated effector cells in the lung and the release of proinflammatory mediators that eventually result in the development of pulmonary fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/31/12794/abstract/17-19\">",
"     17-19",
"    </a>",
"    ]. Nude (athymic) mice are resistant to bleomycin-induced lung injury, suggesting that the inflammatory process is important to the pathogenesis of the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?12/31/12794/abstract/20\">",
"     20",
"    </a>",
"    ]. In contrast, SCID mice are not resistant, suggesting that T lymphocytes do not play a profibrotic role in the murine model of bleomycin-induced fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/31/12794/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The importance of inflammatory cytokines in the development of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    -induced lung injury is suggested by several observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Activation of messenger RNA-encoding cytokines after",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"       bleomycin",
"      </a>",
"      exposure in whole lung and bronchoalveolar lavage preparations precedes the proliferative response and the induction of collagen synthesis [",
"      <a class=\"abstract\" href=\"UTD.htm?12/31/12794/abstract/17,22,23\">",
"       17,22,23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In animal models, neutralization of the biologic activity of proinflammatory cytokines, with neutralizing antibodies (eg, anti-tumor necrosis factor alpha (TNFa) and anti-transforming growth factor (TGF)-beta), soluble receptors (eg, recombinant human TNFa receptors) or receptor antagonists (eg, interleukin (IL)-1 receptor antagonists) that bind and inactivate corresponding peptides, results in the amelioration of the lung fibrotic process induced by",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"       bleomycin",
"      </a>",
"      &nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?12/31/12794/abstract/18,24,25\">",
"       18,24,25",
"      </a>",
"      ]. Furthermore, animals in which the TNFa receptors have been deleted by recombinant technology are protected from the development of bleomycin-induced lung injury and fibrosis [",
"      <a class=\"abstract\" href=\"UTD.htm?12/31/12794/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Mice that lack the gene encoding cytosolic phospholipase A2, a key enzyme in the generation of proinflammatory thromboxanes and leukotrienes, have an attenuated fibrotic response following",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"       bleomycin",
"      </a>",
"      administration [",
"      <a class=\"abstract\" href=\"UTD.htm?12/31/12794/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The alveolar macrophage (AM) is thought to play a central role in the development of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    -induced lung injury due to its ability to release a number of effector molecules (eg, cytokines, lipid metabolites, oxygen radicals). The mechanism for activation of the AM by bleomycin is unknown. Bleomycin receptors have been identified on the surface of rat AMs, suggesting that activation might be mediated through a second messenger [",
"    <a class=\"abstract\" href=\"UTD.htm?12/31/12794/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One report, using mice engrafted with bone marrow isolated from transgenic mice expressing enhanced green fluorescent protein, found that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    treatment induces migration of fibroblasts from the bone marrow to the lung [",
"    <a class=\"abstract\" href=\"UTD.htm?12/31/12794/abstract/28\">",
"     28",
"    </a>",
"    ]. These fibroblasts express type I collagen, telomerase, and CXCR4 and CCR7 chemokine receptors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    -induced pulmonary fibrosis is largely dependent on cumulative drug dose. In patients exposed to a total of 270 units or less (one unit = 1 mg), high-grade lung toxicity is seen in 0 to 2 percent, while rates among patients receiving doses of 360 units or more range from 6 to 18 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?12/31/12794/abstract/2,29-32\">",
"     2,29-32",
"    </a>",
"    ]. In trials of standard-dose chemotherapy for germ cell tumors (three or four cycles, which contain a cumulative bleomycin dose of 270 or 360 units), fatal pulmonary toxicity rates have been in the range of 0 to 1 and 0 to 3 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?12/31/12794/abstract/29-36\">",
"     29-36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/63/24568?source=see_link\">",
"     \"Initial risk-stratified treatment for advanced testicular germ cell tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Age, cumulative drug dose, renal function, the severity of the underlying malignancy at presentation, and also concomitant use of oxygen, radiation therapy, other chemotherapeutic agents, and hematopoietic colony stimulating factors may all influence the risk of developing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    lung toxicity (",
"    <a class=\"graphic graphic_table graphicRef75966 \" href=\"UTD.htm?3/22/3435\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?12/31/12794/abstract/3,5,37\">",
"     3,5,37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Age",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    -induced lung toxicity appears higher in older patients, as evidenced by the following data:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The United Kingdom Royal Marsden NHS Trust reported that among 835 patients treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"       bleomycin",
"      </a>",
"      -containing regimens for germ cell tumors, age over 40 was associated with a 2.3-fold higher risk of pulmonary complications [",
"      <a class=\"abstract\" href=\"UTD.htm?12/31/12794/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a study of 141 patients with Hodgkin lymphoma who received regimens including",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"       bleomycin",
"      </a>",
"      , the mean age of those with and without bleomycin toxicity was 49 versus 29 years [",
"      <a class=\"abstract\" href=\"UTD.htm?12/31/12794/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A Scottish study of 194 patients treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"       bleomycin",
"      </a>",
"      for germ cell tumors reported that the median age of the five patients who died of pulmonary toxicity was 55 compared to a median age of 33 among those who did not develop fatal pulmonary toxicity [",
"      <a class=\"abstract\" href=\"UTD.htm?12/31/12794/abstract/38\">",
"       38",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cumulative doses &gt;400 units are associated with higher rates of pulmonary toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?12/31/12794/abstract/39\">",
"     39",
"    </a>",
"    ]. Although high-grade lung injury is very rare with cumulative doses under 400 units, injury can occur at doses less than 50 units. Rapid intravenous infusion may also increase the risk of toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?12/31/12794/abstract/40,41\">",
"     40,41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Other chemotherapy drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the treatment of testicular germ cell tumors,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    is administered in conjunction with other chemotherapy agents, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    . At least some data suggest that high cumulative doses of cisplatin also contribute to late impairment of pulmonary function and restrictive lung disease in long-term testicular cancer survivors [",
"    <a class=\"abstract\" href=\"UTD.htm?12/31/12794/abstract/42\">",
"     42",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/49/20250?source=see_link&amp;anchor=H5#H5\">",
"     \"Treatment-related toxicity in men with testicular germ cell tumors\", section on 'Late chemotherapy toxicity'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Similarly, concomitant",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    may increase the risk of pulmonary toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?12/31/12794/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     High fraction of inspired oxygen",
"    </span>",
"    &nbsp;&mdash;&nbsp;In animal models, simultaneous exposure to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    and high concentrations of inspired oxygen increases the risk of bleomycin-induced lung injury, whereas exposure to lower than normal oxygen concentrations appears protective [",
"    <a class=\"abstract\" href=\"UTD.htm?12/31/12794/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. A study evaluating the effect of high concentrations of inspired oxygen in hamsters noted that the increased pulmonary toxicity with high inspired oxygen concentration was only seen with simultaneous exposure to bleomycin and did not occur when the bleomycin treatment preceded the oxygen exposure by more than one month [",
"    <a class=\"abstract\" href=\"UTD.htm?12/31/12794/abstract/46\">",
"     46",
"    </a>",
"    ]. Whether any of these data apply to humans is not clear.",
"   </p>",
"   <p>",
"    The evidence that oxygen exposure may increase the risk of pulmonary toxicity in humans is largely anecdotal:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute respiratory failure from adult respiratory distress syndrome has been reported following general anesthesia in patients previously treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"       bleomycin",
"      </a>",
"      &nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?12/31/12794/abstract/47-49\">",
"       47-49",
"      </a>",
"      ]. Following the death of five bleomycin-treated patients from postoperative pulmonary complications at a single institution, a new intraoperative protocol was developed in which oxygen exposure was minimized and intravenous fluid replacement was judiciously administered [",
"      <a class=\"abstract\" href=\"UTD.htm?12/31/12794/abstract/47\">",
"       47",
"      </a>",
"      ]. With adoption of this protocol, none of the subsequent 12 patients who underwent post-bleomycin surgery for metastatic germ cell tumors developed pneumonitis or died from postoperative pulmonary complications.",
"     </li>",
"     <li>",
"      Several reports document that exposure to supplemental oxygen was followed by a recurrence of lung injury in patients who had previously had",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"       bleomycin",
"      </a>",
"      pneumonitis; although in some cases the inspired fraction of oxygen was only 33 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?12/31/12794/abstract/49\">",
"       49",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Not all of the data regarding the effect of oxygen on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    lung injury are consistent, however. A review of 77 patients undergoing major surgery following bleomycin-containing chemotherapy failed to demonstrate a correlation between perioperative oxygen restriction and either postoperative pulmonary morbidity or survival [",
"    <a class=\"abstract\" href=\"UTD.htm?12/31/12794/abstract/50\">",
"     50",
"    </a>",
"    ]. These authors suggested that careful fluid management during surgery was more important than oxygen restriction.",
"   </p>",
"   <p>",
"    Nonetheless, the anecdotal data in humans, combined with the animal data, have had a dramatic impact on clinical practice and have led to widespread recommendations for lifelong avoidance of high concentrations of supplemental oxygen in patients previously exposed to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    unless necessary to maintain an adequate arterial oxygen saturation. It is unknown whether a threshold fraction of inspired oxygen or duration of therapy exists above which the risk of lung injury rises, or whether there is an interval following bleomycin treatment after which higher oxygen concentrations will not increase the risk of lung injury. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/47/28407?source=see_link\">",
"     \"Oxygen toxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Radiation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thoracic irradiation increases the risk of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    lung toxicity, whether it is administered prior to or simultaneously with bleomycin. It is unclear whether a long interval between irradiation and administration of bleomycin eliminates the increased risk of lung injury. However, preliminary evidence from a study of 15 patients with advanced-stage Hodgkin lymphoma suggests that the risk of pulmonary toxicity during consolidative irradiation is low when there is an interval of at least four weeks between chemotherapy and irradiation [",
"    <a class=\"abstract\" href=\"UTD.htm?12/31/12794/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Renal insufficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal insufficiency is a risk factor for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?12/31/12794/abstract/5,51\">",
"     5,51",
"    </a>",
"    ]. This is not surprising since more than 80 percent of the drug is rapidly eliminated by the kidney in normal individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?12/31/12794/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H548953\">",
"    <span class=\"h2\">",
"     Cigarette smoking",
"    </span>",
"    &nbsp;&mdash;&nbsp;It has been suggested that cigarette smoking is a risk factor for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    pulmonary toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?12/31/12794/abstract/4,53,54\">",
"     4,53,54",
"    </a>",
"    ], largely based on a single retrospective series in which pulmonary toxicity, as assessed radiographically, was noted in 55 percent of cigarette smokers and none of the nonsmokers [",
"    <a class=\"abstract\" href=\"UTD.htm?12/31/12794/abstract/54\">",
"     54",
"    </a>",
"    ]. However, others have not found an association between smoking and bleomycin pulmonary toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?12/31/12794/abstract/51,55-58\">",
"     51,55-58",
"    </a>",
"    ]. The discrepancy may be due to other confounding factors such as bleomycin dose, renal function, the use of other chemotherapeutic agents, and thoracic irradiation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Colony stimulating factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Concomitant treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/13/23767?source=see_link\">",
"     granulocyte colony-stimulating factor",
"    </a>",
"    (G-CSF) (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/13/23767?source=see_link\">",
"     filgrastim",
"    </a>",
"    ) was identified as a possible risk factor for the development of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    -induced lung injury in animal studies. However, data in humans are conflicting as to whether G-CSF increases the risk of bleomycin-induced pulmonary toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?12/31/12794/abstract/11,37,59-63\">",
"     11,37,59-63",
"    </a>",
"    ]. One reason for the disparate results may be the confounding influence of age on the incidence of bleomycin lung toxicity. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Epidemiology'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Regardless, many clinicians avoid using G-CSF in regimens containing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    , particularly ABVD (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    , bleomycin,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/3/4152?source=see_link\">",
"     vinblastine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/49/4887?source=see_link\">",
"     dacarbazine",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/54/39786?source=see_link\">",
"     \"Initial treatment of advanced (stage III-IV) classical Hodgkin lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptoms and physical signs associated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    -induced lung injury are nonspecific (",
"    <a class=\"graphic graphic_table graphicRef54965 \" href=\"UTD.htm?29/59/30651\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?12/31/12794/abstract/4\">",
"     4",
"    </a>",
"    ]. However, the time course of onset of clinical manifestations may suggest a particular type of lung injury, as described below.",
"   </p>",
"   <p>",
"    Symptoms of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    -induced interstitial lung disease usually develop subacutely between one and six months after bleomycin treatment, but may occur during therapy or more than six months following the administration of bleomycin [",
"    <a class=\"abstract\" href=\"UTD.htm?12/31/12794/abstract/64\">",
"     64",
"    </a>",
"    ]. Symptoms and signs include nonproductive cough, dyspnea, pleuritic or substernal chest pain, fever, tachypnea, auscultatory crackles, lung restriction, and hypoxemia.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     Bleomycin",
"    </a>",
"    -induced hypersensitivity pneumonitis may present with more rapidly progressive symptoms.",
"   </p>",
"   <p>",
"    An acute chest pain syndrome occurs in approximately 1 percent of patients during infusion of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    , but does not predict the development of pulmonary fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/31/12794/abstract/65\">",
"     65",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/57/43930?source=see_link&amp;anchor=H50#H50\">",
"     \"Infusion reactions to systemic chemotherapy\", section on 'Bleomycin'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evaluation of patients with suspected",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    -induced lung injury typically includes a complete blood count with differential, radiographic imaging, and pulmonary function testing. Many patients will also undergo bronchoscopy with bronchoalveolar lavage to rule out infection or malignancy. Lung biopsy is typically reserved for patients in whom the diagnosis remains unclear after initial testing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Laboratory",
"    </span>",
"    &nbsp;&mdash;&nbsp;Occasionally, a mild peripheral blood eosinophilia will be noted in patients with hypersensitivity pneumonitis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/31/12794/abstract/66\">",
"     66",
"    </a>",
"    ]. For patients with germ cell tumors, certain blood tests (eg, human chorionic gonadotropin [hCG] and alpha fetoprotein [AFP], lactate dehydrogenase [LDH]) may be used to assess whether metastasis to the lungs might be an alternate explanation for the findings suggestive of interstitial lung disease, although interstitial pulmonary involvement by germ cell tumors is rare. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/58/38822?source=see_link\">",
"     \"Serum tumor markers in testicular germ cell tumors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/56/2954?source=see_link&amp;anchor=H2#H2\">",
"     \"Treatment of relapsed and refractory testicular germ cell tumors\", section on 'Diagnosis of relapsed disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;A chest radiograph is usually obtained to evaluate symptoms, such as dyspnea, cough, or chest pain, or signs such as crackles on lung exam or hypoxemia. The appearance of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    -induced lung injury on chest radiographs is variable (",
"    <a class=\"graphic graphic_table graphicRef75991 \" href=\"UTD.htm?0/25/411\">",
"     table 3",
"    </a>",
"    ). The classic pattern of bleomycin-induced pulmonary fibrosis includes bibasilar subpleural opacification with volume loss and blunting of the costophrenic angles; however, fine nodular densities may also be present. These early findings may evolve to progressive consolidation and honeycombing. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/62/5096?source=see_link\">",
"     \"Evaluation of diffuse lung disease by conventional chest radiography\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pneumothorax",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pneumomediastinum are rare complications of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    -induced pulmonary fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/31/12794/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    High-resolution computed tomography (HRCT) of the chest is used to characterize the pattern, location, and extent of abnormalities noted on a chest radiograph and to evaluate gas transfer abnormalities noted on pulmonary function tests. HRCT is generally not used as a screening tool for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    -induced lung injury, although HRCT is more sensitive than chest radiograph in identifying lung abnormalities in bleomycin-exposed patients [",
"    <a class=\"abstract\" href=\"UTD.htm?12/31/12794/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    HRCT patterns associated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    toxicity usually reflect the underlying histopathology [",
"    <a class=\"abstract\" href=\"UTD.htm?12/31/12794/abstract/69\">",
"     69",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/23/4474?source=see_link\">",
"     \"Idiopathic interstitial pneumonias: Clinical manifestations and pathology\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Diffuse alveolar damage is usually associated with airspace consolidation or ground glass opacities in dependent locations.",
"     </li>",
"     <li>",
"      Findings suggestive of end-stage fibrosis include extensive reticular markings at the lung periphery, traction bronchiectasis, and honeycombing.",
"     </li>",
"     <li>",
"      Findings suggestive of nonspecific interstitial pneumonia include ground glass opacities, increased reticular markings in a subpleural location, and bronchiolectasis.",
"     </li>",
"     <li>",
"      Organizing pneumonia is manifest by ground glass opacities in a bilateral but asymmetric pattern or by airspace consolidation in a subpleural or peribronchial distribution. In the setting of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"       bleomycin",
"      </a>",
"      toxicity, organizing pneumonia may rarely present as one or more nodular densities that may mimic tumor metastases [",
"      <a class=\"abstract\" href=\"UTD.htm?12/31/12794/abstract/68,70\">",
"       68,70",
"      </a>",
"      ]. Often, the abnormalities are in a subpleural location.",
"     </li>",
"     <li>",
"      Hypersensitivity pneumonitis presents with diffuse, bilateral ground glass opacities",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      centrilobular nodules [",
"      <a class=\"abstract\" href=\"UTD.htm?12/31/12794/abstract/69\">",
"       69",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/29/16858?source=see_link\">",
"       \"High resolution computed tomography of the lungs\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is important not to confuse new inflammatory nodules due to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    with progressive cancer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Pulmonary function testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many clinicians obtain a baseline set of pulmonary function tests (PFT) before starting",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    ; this practice is recommended in guidelines from the National Comprehensive Cancer Network (NCCN) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/31/12794/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Subsequently, PFTs are usually obtained only to evaluate dyspnea, cough, crackles on chest examination, or an abnormal chest radiograph. The majority of patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    will have a decrease in their diffusing capacity for carbon monoxide (DLCO) and those with significant pulmonary toxicity will have a decrease in lung volumes (eg, forced vital capacity [FVC] and total lung capacity [TLC]). As an example, two randomized trials comparing a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    , plus bleomycin regimen versus cisplatin plus etoposide alone without bleomycin reported a median decline in DLCO of 14 to 20 percent in the bleomycin arms compared to 0 to 2 percent without bleomycin [",
"    <a class=\"abstract\" href=\"UTD.htm?12/31/12794/abstract/31,35\">",
"     31,35",
"    </a>",
"    ]. However, only a small percentage of patients exposed to bleomycin develop clinical signs or symptoms of lung toxicity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Screening for lung toxicity during therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;DLCO initially appeared to be a useful test to screen for early pulmonary toxicity; however, subsequent data has questioned its use as a screening test. In early clinical trials, decreases in lung volumes and DLCO appeared to precede the development of severe",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    lung damage, and a decline in DLCO appeared to be the earliest and most sensitive indicator of subclinical lung injury [",
"    <a class=\"abstract\" href=\"UTD.htm?12/31/12794/abstract/72,73\">",
"     72,73",
"    </a>",
"    ]. Subsequently, it has become apparent that PFTs, including DLCO, are neither sensitive nor specific for bleomycin lung toxicity, and many have questioned the clinical significance of these changes [",
"    <a class=\"abstract\" href=\"UTD.htm?12/31/12794/abstract/74-77\">",
"     74-77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A particular concern is that routine screening for pulmonary toxicity with DLCO results in many false positive results, which may lead to the premature and unnecessary discontinuation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    . The clinical consequences include inferior cancer control",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    toxicity due to the substitution of an alternative, more toxic agent for the bleomycin.",
"   </p>",
"   <p>",
"    In practice, the approach to screening for incipient pulmonary toxicity among patients receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    is variable and inconsistent, as evidenced by the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Many institutions, including ours, do not monitor DLCO or other PFTs during",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"       bleomycin",
"      </a>",
"      therapy. Guidelines from the National Comprehensive Cancer Network (NCCN) recommend only that baseline pulmonary function tests be \"considered\" at baseline, and repeated only as clinically indicated [",
"      <a class=\"abstract\" href=\"UTD.htm?12/31/12794/abstract/71\">",
"       71",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Many centers perform serial monitoring of DLCO in patients receiving",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"       bleomycin",
"      </a>",
"      . Baseline PFTs are established prior to administration of bleomycin, and then repeated periodically, often prior to each cycle as cumulative doses approach 400 units. Several authors recommend that bleomycin be discontinued if the DLCO falls to less than 60 percent of an individual's baseline value [",
"      <a class=\"abstract\" href=\"UTD.htm?12/31/12794/abstract/55,78,79\">",
"       55,78,79",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The US Food and Drug Administration-approved package insert recommends frequent chest radiographs in patients receiving",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"       bleomycin",
"      </a>",
"      , and optional monthly determinations of DLCO with discontinuation of drug when the DLCO falls to below 30 to 35 percent of the pretreatment value [",
"      <a class=\"abstract\" href=\"UTD.htm?12/31/12794/abstract/80\">",
"       80",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Monitoring of uptake on 18-fluorodeoxyglucose (FDG) positron emission tomography (PET) scanning is being evaluated as another potential screening tool for early detection of drug-induced pulmonary injury, but the data are limited, and this is not a standard approach [",
"    <a class=\"abstract\" href=\"UTD.htm?12/31/12794/abstract/81,82\">",
"     81,82",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Bronchoalveolar lavage",
"    </span>",
"    &nbsp;&mdash;&nbsp;The main role for bronchoalveolar lavage (BAL) in assessing possible",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    lung toxicity is to exclude infection or malignancy as causes of radiographic abnormalities. Data regarding typical BAL findings in bleomycin lung toxicity are limited. In one report, neutrophilia was most common, although eosinophilia may be seen in BAL samples from patients with hypersensitivity pneumonitis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/31/12794/abstract/3,83,84\">",
"     3,83,84",
"    </a>",
"    ]. Cytologic atypia with hyperchromatic, multinucleated cells and prominent macronucleoli may also be seen [",
"    <a class=\"abstract\" href=\"UTD.htm?12/31/12794/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Lung biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A video-assisted thoracoscopic or open lung biopsy is usually obtained when the etiology of symptoms, signs, and radiographic abnormalities remains unclear after the above evaluation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/26/424?source=see_link&amp;anchor=H2#H2\">",
"     \"Role of lung biopsy in the diagnosis of interstitial lung disease\", section on 'Indications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Gross lung specimens from subjects with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    -induced lung injury typically demonstrate a subpleural distribution of lung injury and fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/31/12794/abstract/2\">",
"     2",
"    </a>",
"    ]. Histopathology is nonspecific, although squamous metaplasia is a characteristic finding [",
"    <a class=\"abstract\" href=\"UTD.htm?12/31/12794/abstract/4\">",
"     4",
"    </a>",
"    ]. Various patterns of interstitial lung disease have been described, including end-stage fibrosis, nonspecific interstitial pneumonia, diffuse alveolar damage, organizing pneumonia, and hypersensitivity (eosinophilic) pneumonia [",
"    <a class=\"abstract\" href=\"UTD.htm?12/31/12794/abstract/69\">",
"     69",
"    </a>",
"    ]. More than one of these patterns may be present at the same time [",
"    <a class=\"abstract\" href=\"UTD.htm?12/31/12794/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For patients with a pattern of diffuse alveolar damage, histopathologic findings include endothelial and type I epithelial cell necrosis, type II epithelial cell hyperplasia, and hyaline membranes. In some patients, the diffuse alveolar damage will resolve, in others it will progress to fibroproliferative lesions and excess collagen deposition.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     Bleomycin",
"    </a>",
"    -induced pulmonary nodules usually have histopathology similar to diffuse alveolar damage, although patterns of granulomatous infiltration, organizing pneumonia (also known as bronchiolitis obliterans organizing pneumonia [BOOP]), and eosinophilia may occur [",
"    <a class=\"abstract\" href=\"UTD.htm?12/31/12794/abstract/3,69,85\">",
"     3,69,85",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/23/4474?source=see_link\">",
"     \"Idiopathic interstitial pneumonias: Clinical manifestations and pathology\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/60/19402?source=see_link\">",
"     \"Cryptogenic organizing pneumonia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hypersensitivity reactions demonstrate eosinophilic pneumonitis with focal consolidation [",
"    <a class=\"abstract\" href=\"UTD.htm?12/31/12794/abstract/84,86\">",
"     84,86",
"    </a>",
"    ]. Other inflammatory cells are also present, including plasma cells, lymphocytes, and mast cells. Focal areas of organizing pneumonia and dysplastic type II epithelial cells may be seen. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/49/19222?source=see_link\">",
"     \"Classification and clinical manifestations of hypersensitivity pneumonitis (extrinsic allergic alveolitis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    -induced pulmonary toxicity is usually made based on the combination of a compatible clinical pattern, a history of treatment with bleomycin, and the exclusion of infection or pulmonary involvement from the underlying malignancy.",
"   </p>",
"   <p>",
"    Sputum analysis may be helpful to evaluate for the presence of infection, but often bronchoalveolar lavage (BAL) is performed for microbiologic or cytologic analysis. BAL findings in",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    -induced lung injury are nonspecific, so BAL is more helpful in the identification of infection or malignancy than in making a specific diagnosis of bleomycin-induced lung injury. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Bronchoalveolar lavage'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    When the diagnosis remains unclear, lung biopsy may be helpful, although histopathologic findings of drug-induced lung toxicity are nonspecific and require correlation with clinical, laboratory and radiographic findings. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/51/25402?source=see_link\">",
"     \"Approach to the immunocompromised patient with fever and pulmonary infiltrates\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/26/424?source=see_link\">",
"     \"Role of lung biopsy in the diagnosis of interstitial lung disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    -induced lung injury includes lung infection, radiation-induced pulmonary fibrosis, metastatic disease, and an adverse reaction to other medications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     Bleomycin",
"    </a>",
"    should be discontinued in all patients with documented or strongly suspected bleomycin-induced lung injury. Treatment with glucocorticoids is reserved for patients with symptomatic lung toxicity, as spontaneous resolution of asymptomatic radiographic opacities has been described [",
"    <a class=\"abstract\" href=\"UTD.htm?12/31/12794/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The response to glucocorticoid therapy varies among the different patterns of pulmonary damage, as described in the following sections. However, for the majority of patients, the specific histologic type of lung toxicity (eg, nonspecific interstitial pneumonia, usual interstitial pneumonia, diffuse alveolar damage) is not definitively established, although organizing pneumonia and eosinophilic hypersensitivity pneumonitis may be strongly suggested based on the radiographic pattern or presence of peripheral blood or bronchoalveolar lavage eosinophilia. Thus, the decision to initiate glucocorticoid therapy is usually made without knowing the exact histopathologic pattern of pulmonary injury.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Interstitial pneumonitis, diffuse alveolar damage, and fibrosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no controlled studies of glucocorticoids or other immunosuppressive drugs for the treatment of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    -induced interstitial pneumonitis, diffuse alveolar damage, or fibrosis, although case reports and case series have described substantial recovery when a significant inflammatory pneumonitis was present [",
"    <a class=\"abstract\" href=\"UTD.htm?12/31/12794/abstract/2,87,88\">",
"     2,87,88",
"    </a>",
"    ]. In a series of ten patients with bleomycin induced lung toxicity, the seven patients who were treated with systemic glucocorticoids experienced significant clinical and radiographic improvements, while the three patients who were not treated with glucocorticoids died [",
"    <a class=\"abstract\" href=\"UTD.htm?12/31/12794/abstract/88\">",
"     88",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The optimal dosing and duration of glucocorticoid therapy for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    -induced lung injury are not known. Based on clinical experience and data from case series, we typically initiate treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    at 0.75 to 1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    (using ideal body weight) per day up to 100 mg per day [",
"    <a class=\"abstract\" href=\"UTD.htm?12/31/12794/abstract/88\">",
"     88",
"    </a>",
"    ]. After four to eight weeks, the dose of prednisone is tapered gradually over an additional four to six months, in accordance with the patient's condition and clinical response.",
"   </p>",
"   <p>",
"    Short-term improvement occurs in 50 to 70 percent of glucocorticoid-treated patients, but symptoms may relapse when therapy is tapered [",
"    <a class=\"abstract\" href=\"UTD.htm?12/31/12794/abstract/88\">",
"     88",
"    </a>",
"    ]. Some patients who respond to glucocorticoid therapy initially may subsequently develop progressive interstitial pulmonary fibrosis that is unresponsive to glucocorticoid therapy. Pulmonary function abnormalities may or may not improve with therapy and may recur after a period of one to five years, even in patients with an initially positive response to glucocorticoids.",
"   </p>",
"   <p>",
"    Some patients who have a later onset of interstitial lung disease after",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    therapy may have a clinical presentation suggestive of usual interstitial pneumonia with progressive fibrosis and less active inflammation. In these patients, the radiographic pattern on high-resolution CT is consistent with usual interstitial pneumonia (eg, increased reticular markings and evidence of honeycombing). These patients may not have glucocorticoid-responsive disease. If a clear response to systemic glucocorticoids does not occur within four to six weeks, we discontinue glucocorticoids to avoid side effects related to long-term glucocorticoid therapy. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Imaging'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/23/4474?source=see_link&amp;anchor=H3#H3\">",
"     \"Idiopathic interstitial pneumonias: Clinical manifestations and pathology\", section on 'Usual interstitial pneumonia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Organizing pneumonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend that patients with symptomatic",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    -induced organizing pneumonia be treated with systemic glucocorticoids, although occasionally, organizing pneumonia will remit without therapy. We usually follow the glucocorticoid dosing used for cryptogenic organizing pneumonia. The initial dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    is usually 0.75 to 1.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day (using ideal body weight) to a maximum of 100",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    given as a single oral dose in the morning. Treatment of cryptogenic organizing pneumonia is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/60/19402?source=see_link&amp;anchor=H12#H12\">",
"     \"Cryptogenic organizing pneumonia\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Hypersensitivity pneumonitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients who are diagnosed with hypersensitivity pneumonitis based on an acute onset of pneumonitis, a radiographic appearance consistent with hypersensitivity pneumonitis, and either bronchoalveolar lavage eosinophilia or histopathologic confirmation, we typically initiate systemic glucocorticoids, after infection is excluded.",
"   </p>",
"   <p>",
"    There are no data regarding the optimal dosing of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    , but the response is usually excellent, as long as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    is discontinued. A reasonable choice is to start with 0.75 to 1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    (based on ideal body weight) per day, to a maximum of 100",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    for the first four to six weeks. In comparison with other forms of bleomycin-induced lung toxicity, there is usually a more rapid response to glucocorticoid treatment, although this is based on anecdotal reports. Tapering of prednisone is usually accomplished over a few months [",
"    <a class=\"abstract\" href=\"UTD.htm?12/31/12794/abstract/86\">",
"     86",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     REINITIATION OF BLEOMYCIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reinitiation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    is generally not recommended in patients with bleomycin-induced pulmonary toxicity and is contraindicated in patients with pulmonary fibrosis. Successful reinitiation of bleomycin in a patient with hypersensitivity pneumonitis related to bleomycin has been described in a couple of case reports [",
"    <a class=\"abstract\" href=\"UTD.htm?12/31/12794/abstract/66,86\">",
"     66,86",
"    </a>",
"    ]. For patients who are thought to have hypersensitivity pneumonitis (as established by high resolution computed tomography, eosinophilia on bronchoalveolar lavage, or histopathology), reinitiation of bleomycin is usually not considered unless there is no equally effective alternative antineoplastic agent for the patient's disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     SUPPLEMENTAL OXYGEN AND FUTURE PERIOPERATIVE MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the evidence is largely anecdotal, and inconsistent, exposure to high inspired oxygen concentrations, even many years following exposure to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    , may increase the risk for pulmonary toxicity. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'High fraction of inspired oxygen'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    For patients with prior",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    exposure who have hypoxemia, supplemental oxygen is administered sparingly to achieve an oxygen saturation of 89 to 92 percent. The priority is to maintain adequate oxygen saturation, even if that requires a high fraction of inspired oxygen (FIO2).",
"   </p>",
"   <p>",
"    For",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    -exposed patients who are undergoing surgery, intravenous fluids are administered sparingly to avoid volume overload and perioperative pulmonary edema [",
"    <a class=\"abstract\" href=\"UTD.htm?12/31/12794/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     FUTURE THERAPIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no studies demonstrating the efficacy of therapies other than glucocorticoids for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    -induced lung injury in humans. However, several drugs have demonstrated efficacy in animal models [",
"    <a class=\"abstract\" href=\"UTD.htm?12/31/12794/abstract/89-99\">",
"     89-99",
"    </a>",
"    ]. Examples include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/26/31141?source=see_link\">",
"       Pirfenidone",
"      </a>",
"      , a novel antifibrotic agent [",
"      <a class=\"abstract\" href=\"UTD.htm?12/31/12794/abstract/92,93\">",
"       92,93",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Relaxin, a novel cytokine that inhibits TGF-beta1-induced expression of collagen types I and III and fibronectin expression in human lung fibroblasts in vitro [",
"      <a class=\"abstract\" href=\"UTD.htm?12/31/12794/abstract/94\">",
"       94",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Pretreatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"       erythromycin",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?12/31/12794/abstract/95\">",
"       95",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Augmentation of the enzyme",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"       bleomycin",
"      </a>",
"      hydrolase within the lungs of bleomycin-treated patients [",
"      <a class=\"abstract\" href=\"UTD.htm?12/31/12794/abstract/96\">",
"       96",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the vast majority of these animal studies, the agents were administered",
"    <strong>",
"     prior",
"    </strong>",
"    to injection of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    . Thus, it remains unknown if they are effective once bleomycin-induced lung injury has been initiated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"       Bleomycin",
"      </a>",
"      is associated with four main types of pulmonary toxicity: subacute progressive pulmonary fibrosis, hypersensitivity pneumonitis, organizing pneumonia, and an acute chest pain syndrome during rapid infusion. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The risk of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"       bleomycin",
"      </a>",
"      -induced lung toxicity appears to be higher in older patients and those with renal insufficiency. Administration of higher doses of bleomycin (&gt;400 units) clearly increases the risk of lung injury, although injury can occur at doses less than 50 units. Thoracic irradiation and concurrent administration of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      at high doses may increase the risk of pulmonary toxicity. Whether smoking increases risk is unclear; however, as a matter of general health, smokers should be encouraged to quit. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The use of pulmonary function tests, particularly the diffusion capacity (DLCO), to screen for early evidence of pulmonary toxicity is controversial. We do not routinely order pulmonary function tests in patients prior to administering",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"       bleomycin",
"      </a>",
"      or during therapy to screen for lung toxicity. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Pulmonary function testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The onset of clinical manifestations usually occurs subacutely between one and six months after",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"       bleomycin",
"      </a>",
"      treatment, but may occur during therapy or more than six months following the administration of bleomycin. Symptoms and signs of bleomycin-induced lung toxicity include nonproductive cough, dyspnea, pleuritic or substernal chest pain, fever, tachypnea, crackles, lung restriction, and hypoxemia. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The classic pattern of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"       bleomycin",
"      </a>",
"      -induced pulmonary fibrosis includes bibasilar subpleural opacities with volume loss and blunting of the costophrenic angles; however, fine nodular densities may also be seen. Honeycombing may develop, as the fibrosis progresses. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Imaging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend permanently discontinuing",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"       bleomycin",
"      </a>",
"      therapy in most patients with documented or strongly suspected bleomycin-induced lung injury (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). Successful reinitiation of bleomycin in a patient with hypersensitivity pneumonitis related to bleomycin has been described. For patients who are thought to have hypersensitivity pneumonitis (as established by high resolution computed tomography, eosinophilia on bronchoalveolar lavage, or histopathology), reinitiation of bleomycin is usually not considered unless there is no equally effective alternative antineoplastic agent for the patient's disease. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Reinitiation of bleomycin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with symptomatic",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"       bleomycin",
"      </a>",
"      -induced pulmonary toxicity and evidence of impairment on pulmonary function tests, we recommend administration of systemic glucocorticoids (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). The usual initial dose is",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      0.75 to 1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      (ideal body weight) per day. After four to six weeks, this dose is gradually tapered. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although the evidence is anecdotal as to whether administration of high inspired fractions of oxygen may provoke or exacerbate pulmonary toxicity several years after treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"       bleomycin",
"      </a>",
"      , we suggest carefully titrating any supplemental oxygen to provide only enough oxygen to maintain the oxygen saturation at 89 to 92 percent (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Supplemental oxygen and future perioperative management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"       bleomycin",
"      </a>",
"      -exposed patients who undergo subsequent surgery, intravenous fluids are administered sparingly to avoid volume overload and perioperative pulmonary edema. (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Supplemental oxygen and future perioperative management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12794/abstract/1\">",
"      Meadors M, Floyd J, Perry MC. Pulmonary toxicity of chemotherapy. Semin Oncol 2006; 33:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12794/abstract/2\">",
"      Jules-Elysee K, White DA. Bleomycin-induced pulmonary toxicity. Clin Chest Med 1990; 11:1.",
"     </a>",
"    </li>",
"    <li>",
"     Camus P. Drug induced infiltrative lung diseases. In: Interstitial Lung Disease, 4th ed, King TE Jr, Schwarz MI (Eds), B.C. Decker, Hamilton, ON, Canada 2003. p.516.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12794/abstract/4\">",
"      Sleijfer S. Bleomycin-induced pneumonitis. Chest 2001; 120:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12794/abstract/5\">",
"      O'Sullivan JM, Huddart RA, Norman AR, et al. Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours. Ann Oncol 2003; 14:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12794/abstract/6\">",
"      Sikic BI. Biochemical and cellular determinants of bleomycin cytotoxicity. Cancer Surv 1986; 5:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12794/abstract/7\">",
"      Chandler DB. Possible mechanisms of bleomycin-induced fibrosis. Clin Chest Med 1990; 11:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12794/abstract/8\">",
"      Fantone JC, Phan SH. Oxygen metabolite detoxifying enzyme levels in bleomycin-induced fibrotic lungs. Free Radic Biol Med 1988; 4:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12794/abstract/9\">",
"      Martin WJ 2nd, Kachel DL. Bleomycin-induced pulmonary endothelial cell injury: evidence for the role of iron-catalyzed toxic oxygen-derived species. J Lab Clin Med 1987; 110:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12794/abstract/10\">",
"      Chandler DB, Barton JC, Briggs DD 3rd, et al. Effect of iron deficiency on bleomycin-induced lung fibrosis in the hamster. Am Rev Respir Dis 1988; 137:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12794/abstract/11\">",
"      Lazo JS, Merrill WW, Pham ET, et al. Bleomycin hydrolase activity in pulmonary cells. J Pharmacol Exp Ther 1984; 231:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12794/abstract/12\">",
"      Harrison JH Jr, Hoyt DG, Lazo JS. Acute pulmonary toxicity of bleomycin: DNA scission and matrix protein mRNA levels in bleomycin-sensitive and -resistant strains of mice. Mol Pharmacol 1989; 36:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12794/abstract/13\">",
"      Hoyt DG, Lazo JS. Murine strain differences in acute lung injury and activation of poly(ADP-ribose) polymerase by in vitro exposure of lung slices to bleomycin. Am J Respir Cell Mol Biol 1992; 7:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12794/abstract/14\">",
"      Schrier DJ, Kunkel RG, Phan SH. The role of strain variation in murine bleomycin-induced pulmonary fibrosis. Am Rev Respir Dis 1983; 127:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12794/abstract/15\">",
"      Harrison JH Jr, Lazo JS. Plasma and pulmonary pharmacokinetics of bleomycin in murine strains that are sensitive and resistant to bleomycin-induced pulmonary fibrosis. J Pharmacol Exp Ther 1988; 247:1052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12794/abstract/16\">",
"      Filderman AE, Genovese LA, Lazo JS. Alterations in pulmonary protective enzymes following systemic bleomycin treatment in mice. Biochem Pharmacol 1988; 37:1111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12794/abstract/17\">",
"      Phan SH, Kunkel SL. Lung cytokine production in bleomycin-induced pulmonary fibrosis. Exp Lung Res 1992; 18:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12794/abstract/18\">",
"      Piguet PF, Collart MA, Grau GE, et al. Tumor necrosis factor/cachectin plays a key role in bleomycin-induced pneumopathy and fibrosis. J Exp Med 1989; 170:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12794/abstract/19\">",
"      Ortiz LA, Lasky J, Hamilton RF Jr, et al. Expression of TNF and the necessity of TNF receptors in bleomycin-induced lung injury in mice. Exp Lung Res 1998; 24:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12794/abstract/20\">",
"      Schrier DJ, Phan SH, McGarry BM. The effects of the nude (nu/nu) mutation on bleomycin-induced pulmonary fibrosis. A biochemical evaluation. Am Rev Respir Dis 1983; 127:614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12794/abstract/21\">",
"      Helene M, Lake-Bullock V, Zhu J, et al. T cell independence of bleomycin-induced pulmonary fibrosis. J Leukoc Biol 1999; 65:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12794/abstract/22\">",
"      Hoyt DG, Lazo JS. Alterations in pulmonary mRNA encoding procollagens, fibronectin and transforming growth factor-beta precede bleomycin-induced pulmonary fibrosis in mice. J Pharmacol Exp Ther 1988; 246:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12794/abstract/23\">",
"      Khalil N, Whitman C, Zuo L, et al. Regulation of alveolar macrophage transforming growth factor-beta secretion by corticosteroids in bleomycin-induced pulmonary inflammation in the rat. J Clin Invest 1993; 92:1812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12794/abstract/24\">",
"      Giri SN, Hyde DM, Hollinger MA. Effect of antibody to transforming growth factor beta on bleomycin induced accumulation of lung collagen in mice. Thorax 1993; 48:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12794/abstract/25\">",
"      Piguet PF, Vesin C, Grau GE, Thompson RC. Interleukin 1 receptor antagonist (IL-1ra) prevents or cures pulmonary fibrosis elicited in mice by bleomycin or silica. Cytokine 1993; 5:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12794/abstract/26\">",
"      Nagase T, Uozumi N, Ishii S, et al. A pivotal role of cytosolic phospholipase A(2) in bleomycin-induced pulmonary fibrosis. Nat Med 2002; 8:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12794/abstract/27\">",
"      Denholm EM, Phan SH. Bleomycin binding sites on alveolar macrophages. J Leukoc Biol 1990; 48:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12794/abstract/28\">",
"      Hashimoto N, Jin H, Liu T, et al. Bone marrow-derived progenitor cells in pulmonary fibrosis. J Clin Invest 2004; 113:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12794/abstract/29\">",
"      Culine S, Kramar A, Th&eacute;odore C, et al. Randomized trial comparing bleomycin/etoposide/cisplatin with alternating cisplatin/cyclophosphamide/doxorubicin and vinblastine/bleomycin regimens of chemotherapy for patients with intermediate- and poor-risk metastatic nonseminomatous germ cell tumors: Genito-Urinary Group of the French Federation of Cancer Centers Trial T93MP. J Clin Oncol 2008; 26:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12794/abstract/30\">",
"      de Wit R, Roberts JT, Wilkinson PM, et al. Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council. J Clin Oncol 2001; 19:1629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12794/abstract/31\">",
"      de Wit R, Stoter G, Kaye SB, et al. Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group. J Clin Oncol 1997; 15:1837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12794/abstract/32\">",
"      Loehrer PJ Sr, Johnson D, Elson P, et al. Importance of bleomycin in favorable-prognosis disseminated germ cell tumors: an Eastern Cooperative Oncology Group trial. J Clin Oncol 1995; 13:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12794/abstract/33\">",
"      Motzer RJ, Nichols CJ, Margolin KA, et al. Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors. J Clin Oncol 2007; 25:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12794/abstract/34\">",
"      Nichols CR, Catalano PJ, Crawford ED, et al. Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study. J Clin Oncol 1998; 16:1287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12794/abstract/35\">",
"      de Wit R, Stoter G, Sleijfer DT, et al. Four cycles of BEP vs four cycles of VIP in patients with intermediate-prognosis metastatic testicular non-seminoma: a randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group. European Organization for Research and Treatment of Cancer. Br J Cancer 1998; 78:828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12794/abstract/36\">",
"      Culine S, Theodore C, Terrier-Lacombe MJ, Droz JP. Are 3 cycles of bleomycin, etoposide and cisplatin or 4 cycles of etoposide and cisplatin equivalent optimal regimens for patients with good risk metastatic germ cell tumors of the testis? The need for a randomized trial. J Urol 1997; 157:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12794/abstract/37\">",
"      Martin WG, Ristow KM, Habermann TM, et al. Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma. J Clin Oncol 2005; 23:7614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12794/abstract/38\">",
"      Simpson AB, Paul J, Graham J, Kaye SB. Fatal bleomycin pulmonary toxicity in the west of Scotland 1991-95: a review of patients with germ cell tumours. Br J Cancer 1998; 78:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12794/abstract/39\">",
"      Blum RH, Carter SK, Agre K. A clinical review of bleomycin--a new antineoplastic agent. Cancer 1973; 31:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12794/abstract/40\">",
"      Carlson RW, Sikic BI. Continuous infusion or bolus injection in cancer chemotherapy. Ann Intern Med 1983; 99:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12794/abstract/41\">",
"      Cooper KR, Hong WK. Prospective study of the pulmonary toxicity of continuously infused bleomycin. Cancer Treat Rep 1981; 65:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12794/abstract/42\">",
"      Haugnes HS, Aass N, Foss&aring; SD, et al. Pulmonary function in long-term survivors of testicular cancer. J Clin Oncol 2009; 27:2779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12794/abstract/43\">",
"      Macann A, Bredenfeld H, M&uuml;ller RP, et al. Radiotherapy does not influence the severe pulmonary toxicity observed with the administration of gemcitabine and bleomycin in patients with advanced-stage Hodgkin's lymphoma treated with the BAGCOPP regimen: a report by the German Hodgkin's Lymphoma Study Group. Int J Radiat Oncol Biol Phys 2008; 70:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12794/abstract/44\">",
"      Tryka AF, Skornik WA, Godleski JJ, Brain JD. Potentiation of bleomycin-induced lung injury by exposure to 70% oxygen. Morphologic assessment. Am Rev Respir Dis 1982; 126:1074.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12794/abstract/45\">",
"      Berend N. Protective effect of hypoxia on bleomycin lung toxicity in the rat. Am Rev Respir Dis 1984; 130:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12794/abstract/46\">",
"      Tryka AF, Godleski JJ, Brain JD. Differences in effects of immediate and delayed hyperoxia exposure on bleomycin-induced pulmonary injury. Cancer Treat Rep 1984; 68:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12794/abstract/47\">",
"      Goldiner PL, Carlon GC, Cvitkovic E, et al. Factors influencing postoperative morbidity and mortality in patients treated with bleomycin. Br Med J 1978; 1:1664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12794/abstract/48\">",
"      Nygaard K, Smith-Erichsen N, Hatlevoll R, Refsum SB. Pulmonary complications after bleomycin, irradiation and surgery for esophageal cancer. Cancer 1978; 41:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12794/abstract/49\">",
"      Gilson AJ, Sahn SA. Reactivation of bleomycin lung toxicity following oxygen administration. A second response to corticosteroids. Chest 1985; 88:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12794/abstract/50\">",
"      Donat SM, Levy DA. Bleomycin associated pulmonary toxicity: is perioperative oxygen restriction necessary? J Urol 1998; 160:1347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12794/abstract/51\">",
"      Kawai K, Hinotsu S, Tomobe M, Akaza H. Serum creatinine level during chemotherapy for testicular cancer as a possible predictor of bleomycin-induced pulmonary toxicity. Jpn J Clin Oncol 1998; 28:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12794/abstract/52\">",
"      Sleijfer S, van der Mark TW, Schraffordt Koops H, Mulder NH. Enhanced effects of bleomycin on pulmonary function disturbances in patients with decreased renal function due to cisplatin. Eur J Cancer 1996; 32A:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12794/abstract/53\">",
"      Chaudhary UB, Haldas JR. Long-term complications of chemotherapy for germ cell tumours. Drugs 2003; 63:1565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12794/abstract/54\">",
"      Lower EE, Strohofer S, Baughman RP. Bleomycin causes alveolar macrophages from cigarette smokers to release hydrogen peroxide. Am J Med Sci 1988; 295:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12794/abstract/55\">",
"      Hirsch A, Vander Els N, Straus DJ, et al. Effect of ABVD chemotherapy with and without mantle or mediastinal irradiation on pulmonary function and symptoms in early-stage Hodgkin's disease. J Clin Oncol 1996; 14:1297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12794/abstract/56\">",
"      Ngeow J, Tan IB, Kanesvaran R, et al. Prognostic impact of bleomycin-induced pneumonitis on the outcome of Hodgkin's lymphoma. Ann Hematol 2011; 90:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12794/abstract/57\">",
"      Ngan HY, Liang RH, Lam WK, Chan TK. Pulmonary toxicity in patients with non-Hodgkin's lymphoma treated with bleomycin-containing combination chemotherapy. Cancer Chemother Pharmacol 1993; 32:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12794/abstract/58\">",
"      Haas CD, Coltman CA Jr, Gottlieb JA, et al. Phase II evaluation of bleomycin. A Southwest oncology Group study. Cancer 1976; 38:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12794/abstract/59\">",
"      Foss&aring; SD, Kaye SB, Mead GM, et al. Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy. European Organization for Research and Treatment of Cancer, Genito-Urinary Group, and the Medical Research Council Testicular Cancer Working Party, Cambridge, United Kingdom. J Clin Oncol 1998; 16:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12794/abstract/60\">",
"      Saxman SB, Nichols CR, Einhorn LH. Pulmonary toxicity in patients with advanced-stage germ cell tumors receiving bleomycin with and without granulocyte colony stimulating factor. Chest 1997; 111:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12794/abstract/61\">",
"      Evens AM, Cilley J, Ortiz T, et al. G-CSF is not necessary to maintain over 99% dose-intensity with ABVD in the treatment of Hodgkin lymphoma: low toxicity and excellent outcomes in a 10-year analysis. Br J Haematol 2007; 137:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12794/abstract/62\">",
"      Wedgwood A, Younes A. Prophylactic use of filgrastim with ABVD and BEACOPP chemotherapy regimens for Hodgkin lymphoma. Clin Lymphoma Myeloma 2007; 8 Suppl 2:S63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12794/abstract/63\">",
"      Younes A, Fayad L, Romaguera J, et al. Safety and efficacy of once-per-cycle pegfilgrastim in support of ABVD chemotherapy in patients with Hodgkin lymphoma. Eur J Cancer 2006; 42:2976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12794/abstract/64\">",
"      Uzel I, Ozguroglu M, Uzel B, et al. Delayed onset bleomycin-induced pneumonitis. Urology 2005; 66:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12794/abstract/65\">",
"      White DA, Schwartzberg LS, Kris MG, Bosl GJ. Acute chest pain syndrome during bleomycin infusions. Cancer 1987; 59:1582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12794/abstract/66\">",
"      Yousem SA, Lifson JD, Colby TV. Chemotherapy-induced eosinophilic pneumonia. Relation to bleomycin. Chest 1985; 88:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12794/abstract/67\">",
"      Sikdar T, MacVicar D, Husband JE. Pneumomediastinum complicating bleomycin related lung damage. Br J Radiol 1998; 71:1202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12794/abstract/68\">",
"      Bellamy EA, Husband JE, Blaquiere RM, Law MR. Bleomycin-related lung damage: CT evidence. Radiology 1985; 156:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12794/abstract/69\">",
"      Silva CI, M&uuml;ller NL. Drug-induced lung diseases: most common reaction patterns and corresponding high-resolution CT manifestations. Semin Ultrasound CT MR 2006; 27:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12794/abstract/70\">",
"      Cohen MB, Austin JH, Smith-Vaniz A, et al. Nodular bleomycin toxicity. Am J Clin Pathol 1989; 92:101.",
"     </a>",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) guidelines. Available at: www.nccn.org (Accessed on May 15, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12794/abstract/72\">",
"      Comis RL, Kuppinger MS, Ginsberg SJ, et al. Role of single-breath carbon monoxide-diffusing capacity in monitoring the pulmonary effects of bleomycin in germ cell tumor patients. Cancer Res 1979; 39:5076.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12794/abstract/73\">",
"      Pascual RS, Mosher MB, Sikand RS, et al. Effects of bleomycin on pulmonary function in man. Am Rev Respir Dis 1973; 108:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12794/abstract/74\">",
"      McKeage MJ, Evans BD, Atkinson C, et al. Carbon monoxide diffusing capacity is a poor predictor of clinically significant bleomycin lung. New Zealand Clinical Oncology Group. J Clin Oncol 1990; 8:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12794/abstract/75\">",
"      Ng AK, Li S, Neuberg D, et al. A prospective study of pulmonary function in Hodgkin's lymphoma patients. Ann Oncol 2008; 19:1754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12794/abstract/76\">",
"      Villani F, De Maria P, Bonfante V, et al. Late pulmonary toxicity after treatment for Hodgkin's disease. Anticancer Res 1997; 17:4739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12794/abstract/77\">",
"      Lewis BM, Izbicki R. Routine pulmonary function tests during bleomycin therapy. Tests may be ineffective and potentially misleading. JAMA 1980; 243:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12794/abstract/78\">",
"      Comis RL. Detecting bleomycin pulmonary toxicity: a continued conundrum. J Clin Oncol 1990; 8:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12794/abstract/79\">",
"      Jensen JL, Goel R, Venner PM. The effect of corticosteroid administration on bleomycin lung toxicity. Cancer 1990; 65:1291.",
"     </a>",
"    </li>",
"    <li>",
"     Blenoxane (Bleomycin for injection). FDA-approved manufacturer's package insert. US National Library of Medicine. www.dailymed.nlm.nih.gov (Accessed on October 22, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12794/abstract/81\">",
"      Buchler T, Bomanji J, Lee SM. FDG-PET in bleomycin-induced pneumonitis following ABVD chemotherapy for Hodgkin's disease--a useful tool for monitoring pulmonary toxicity and disease activity. Haematologica 2007; 92:e120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12794/abstract/82\">",
"      von Rohr L, Klaeser B, Joerger M, et al. Increased pulmonary FDG uptake in bleomycin-associated pneumonitis. Onkologie 2007; 30:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12794/abstract/83\">",
"      White DA, Kris MG, Stover DE. Bronchoalveolar lavage cell populations in bleomycin lung toxicity. Thorax 1987; 42:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12794/abstract/84\">",
"      Flieder DB, Travis WD. Pathologic characteristics of drug-induced lung disease. Clin Chest Med 2004; 25:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12794/abstract/85\">",
"      Santrach PJ, Askin FB, Wells RJ, et al. Nodular form of bleomycin-related pulmonary injury in patients with osteogenic sarcoma. Cancer 1989; 64:806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12794/abstract/86\">",
"      Holoye PY, Luna MA, MacKay B, Bedrossian CW. Bleomycin hypersensitivity pneumonitis. Ann Intern Med 1978; 88:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12794/abstract/87\">",
"      Maher J, Daly PA. Severe bleomycin lung toxicity: reversal with high dose corticosteroids. Thorax 1993; 48:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12794/abstract/88\">",
"      White DA, Stover DE. Severe bleomycin-induced pneumonitis. Clinical features and response to corticosteroids. Chest 1984; 86:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12794/abstract/89\">",
"      Nici L, Santos-Moore A, Kuhn C, Calabresi P. Modulation of bleomycin-induced pulmonary toxicity in the hamster by the antioxidant amifostine. Cancer 1998; 83:2008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12794/abstract/90\">",
"      Ortiz LA, Lasky JA, Safah H, et al. Exacerbation of bleomycin-induced lung injury in mice by amifostine. Am J Physiol 1999; 277:L1239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12794/abstract/91\">",
"      Entzian P, Gerlach C, Gerdes J, et al. [Pentoxifylline inhibits experimental bleomycin-induced fibrosing alveolitis]. Pneumologie 1997; 51:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12794/abstract/92\">",
"      Schelegle ES, Mansoor JK, Giri S. Pirfenidone attenuates bleomycin-induced changes in pulmonary functions in hamsters. Proc Soc Exp Biol Med 1997; 216:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12794/abstract/93\">",
"      Iyer SN, Margolin SB, Hyde DM, Giri SN. Lung fibrosis is ameliorated by pirfenidone fed in diet after the second dose in a three-dose bleomycin-hamster model. Exp Lung Res 1998; 24:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12794/abstract/94\">",
"      Unemori EN, Pickford LB, Salles AL, et al. Relaxin induces an extracellular matrix-degrading phenotype in human lung fibroblasts in vitro and inhibits lung fibrosis in a murine model in vivo. J Clin Invest 1996; 98:2739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12794/abstract/95\">",
"      Azuma A, Furuta T, Enomoto T, et al. Preventive effect of erythromycin on experimental bleomycin-induced acute lung injury in rats. Thorax 1998; 53:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12794/abstract/96\">",
"      Sebti SM, Mignano JE, Jani JP, et al. Bleomycin hydrolase: molecular cloning, sequencing, and biochemical studies reveal membership in the cysteine proteinase family. Biochemistry 1989; 28:6544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12794/abstract/97\">",
"      Otsuka M, Takahashi H, Shiratori M, et al. Reduction of bleomycin induced lung fibrosis by candesartan cilexetil, an angiotensin II type 1 receptor antagonist. Thorax 2004; 59:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12794/abstract/98\">",
"      Keogh KA, Standing J, Kane GC, et al. Angiotensin II antagonism fails to ameliorate bleomycin-induced pulmonary fibrosis in mice. Eur Respir J 2005; 25:708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/31/12794/abstract/99\">",
"      Aono Y, Nishioka Y, Inayama M, et al. Imatinib as a novel antifibrotic agent in bleomycin-induced pulmonary fibrosis in mice. Am J Respir Crit Care Med 2005; 171:1279.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4316 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-189.41.181.191-9843F0D5B8-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_31_12794=[""].join("\n");
var outline_f12_31_12794=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H30\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PHARMACOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Dose",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Other chemotherapy drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      High fraction of inspired oxygen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Renal insufficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H548953\">",
"      Cigarette smoking",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Colony stimulating factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Laboratory",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Pulmonary function testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Screening for lung toxicity during therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Bronchoalveolar lavage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Lung biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Interstitial pneumonitis, diffuse alveolar damage, and fibrosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Organizing pneumonia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Hypersensitivity pneumonitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      REINITIATION OF BLEOMYCIN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      SUPPLEMENTAL OXYGEN AND FUTURE PERIOPERATIVE MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      FUTURE THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/4316\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4316|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/22/3435\" title=\"table 1\">",
"      Risk factors for bleomycin toxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/59/30651\" title=\"table 2\">",
"      Bleomycin lung injury symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/25/411\" title=\"table 3\">",
"      Bleomycin pneumonitis appearance",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/51/25402?source=related_link\">",
"      Approach to the immunocompromised patient with fever and pulmonary infiltrates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/49/19222?source=related_link\">",
"      Classification and clinical manifestations of hypersensitivity pneumonitis (extrinsic allergic alveolitis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/60/19402?source=related_link\">",
"      Cryptogenic organizing pneumonia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/62/5096?source=related_link\">",
"      Evaluation of diffuse lung disease by conventional chest radiography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/29/16858?source=related_link\">",
"      High resolution computed tomography of the lungs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/23/4474?source=related_link\">",
"      Idiopathic interstitial pneumonias: Clinical manifestations and pathology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/57/43930?source=related_link\">",
"      Infusion reactions to systemic chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/63/24568?source=related_link\">",
"      Initial risk-stratified treatment for advanced testicular germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/54/39786?source=related_link\">",
"      Initial treatment of advanced (stage III-IV) classical Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/47/28407?source=related_link\">",
"      Oxygen toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/26/424?source=related_link\">",
"      Role of lung biopsy in the diagnosis of interstitial lung disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/58/38822?source=related_link\">",
"      Serum tumor markers in testicular germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/56/2954?source=related_link\">",
"      Treatment of relapsed and refractory testicular germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/49/20250?source=related_link\">",
"      Treatment-related toxicity in men with testicular germ cell tumors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_31_12795="Physical properties O2 air helium";
var content_f12_31_12795=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F53132&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F53132&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Physical properties of oxygen, air, and helium",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Density",
"       </td>",
"       <td class=\"subtitle1\">",
"        Viscosity",
"       </td>",
"       <td class=\"subtitle1\">",
"        Thermoconductivity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        (g/L)",
"       </td>",
"       <td class=\"subtitle2\">",
"        (&micro;poise)",
"       </td>",
"       <td class=\"subtitle2\">",
"        (&micro;cal &middot; cm &middot; s",
"&middot; &deg;K)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Oxygen",
"       </td>",
"       <td>",
"        1.429",
"       </td>",
"       <td>",
"        192.6",
"       </td>",
"       <td>",
"        58.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Air",
"       </td>",
"       <td>",
"        1.293",
"       </td>",
"       <td>",
"        170.8",
"       </td>",
"       <td>",
"        58.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Helium",
"       </td>",
"       <td>",
"        0.179",
"       </td>",
"       <td>",
"        188.7",
"       </td>",
"       <td>",
"        352.0",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_31_12795=[""].join("\n");
var outline_f12_31_12795=null;
var title_f12_31_12796="Ischemic forearm exercise test";
var content_f12_31_12796=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F71745&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F71745&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Ischemic forearm exercise test",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        Normal response to ischemic exercise",
"       </td>",
"       <td class=\"subtitle1\">",
"        Lactate",
"       </td>",
"       <td class=\"subtitle1\">",
"        Pyruvate",
"       </td>",
"       <td class=\"subtitle1\">",
"        Ammonia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        3-5 fold increase",
"       </td>",
"       <td class=\"subtitle2\">",
"        3-5 fold increase",
"       </td>",
"       <td class=\"subtitle2\">",
"        5-10 fold increase",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Glycolytic/glycogenolytic defects",
"       </td>",
"       <td>",
"        No rise or &lt;2 fold increase",
"       </td>",
"       <td>",
"        No rise or &lt;2 fold increase",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"4\" rowspan=\"1\">",
"        Except:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Phosphorylase b kinase deficiency",
"       </td>",
"       <td class=\"sublist_other\">",
"        Normal - mildly increased",
"       </td>",
"       <td class=\"sublist_other\">",
"        Normal - mildly increased",
"       </td>",
"       <td class=\"sublist_other\">",
"        Normal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Acid maltase deficiency",
"       </td>",
"       <td class=\"sublist_other\">",
"        Normal",
"       </td>",
"       <td class=\"sublist_other\">",
"        Normal",
"       </td>",
"       <td class=\"sublist_other\">",
"        Normal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Lactate dehydrogenase deficiency",
"       </td>",
"       <td class=\"sublist_other\">",
"        No rise",
"       </td>",
"       <td class=\"sublist_other\">",
"        Normal to markedly increased",
"       </td>",
"       <td class=\"sublist_other\">",
"        Normal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fatty acid oxidation defects",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mitochondrial defects",
"       </td>",
"       <td>",
"        Normal to increased",
"       </td>",
"       <td>",
"        Normal to increased",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Myoadenylate deficiency",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        No rise",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_31_12796=[""].join("\n");
var outline_f12_31_12796=null;
var title_f12_31_12797="Collecting tubule transport";
var content_f12_31_12797=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F60693&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F60693&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Ion transport in collecting tubule principal cells",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 417px; height: 218px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Schematic representation of sodium and potassium transport in the sodium reabsorbing principal cells in the collecting tubules. The entry of filtered Na into these cells is mediated by selective sodium channels in the apical (luminal) membrane (ENaC); the energy for this process is provided by the favorable electrochemical gradient for Na (cell interior electronegative and low cell Na concentration). Reabsorbed Na is pumped out of the cell by the Na-K-ATPase pump in the basolateral (peritubular) membrane. The reabsorption of cationic Na makes the lumen electronegative, thereby creating a favorable gradient for the secretion of K into the lumen via K channels (ROMK and BK) in the apical membrane. Aldosterone, after combining with the cytosolic mineralocorticoid receptor (Aldo-R), leads to enhanced Na reabsorption and potassium secretion by increasing both the number of open Na channels and the number of Na-K-ATPase pumps. ANP inhibits sodium reabsorption by closing the Na channels. The potassium-sparing diuretics (amiloride and triamterene) act by directly inhibiting the epithelial sodium channel; spironolactone acts by competing with aldosterone for binding to the mineralocorticoid receptor.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_31_12797=[""].join("\n");
var outline_f12_31_12797=null;
var title_f12_31_12798="Creation congenic strain";
var content_f12_31_12798=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F63654&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F63654&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Creation of a congenic strain",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 280px; height: 377px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A highly schematic representation of the relative contributions of donor and recipient alleles at sequential generations of backcrossing. The donor contribution is indicated in white and the recipient contribution is indicated in black with the checkerboard pattern indicative of heterozygous loci. By the tenth generation of backcrossing, the differential segment around the selected locus will represent the major contribution from the donor genome.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Professor Lee M. Silver, Princeton University, for use of this illustration, which appeared originally in \"Mouse Genetics,\" published in hardcopy by Oxford University Press, and online by the Jackson Laboratory (file://www.jax.org).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_31_12798=[""].join("\n");
var outline_f12_31_12798=null;
var title_f12_31_12799="Regulation of erythropoiesis";
var content_f12_31_12799=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F70092&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F70092&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 531px\">",
"   <div class=\"ttl\">",
"    Formation of erythyroid progenitors",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 511px; height: 463px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Schematic representation of the formation of erythroid progenitors (BFU-E and CFU-E) from hematopoietic stem cells and multipotent progenitor cells. The transcription factors important for the maturation and differentiation of hematopoietic stem cells (HSC) and expansion of the stem/progenitor compartment are indicated on the right, according to whether they are important for primary erythropoiesis in the yolk sac and/or definitive erythropoiesis in the fetal liver and/or bone marrow. Certain growth factors and their receptors, such as Steel factor (SF)/c-kit and erythropoietin (Epo/EpoR), are important or essential for erythropoiesis, respectively; by comparison, other growth factors, such as IL-3 or GM-CSF, act synergistically but are not essential.",
"    <div class=\"footnotes\">",
"     Epo and EpoR: erythropoietin and its receptor, respectively; SF and W (c-kit): Steel factor and its receptor, respectively; IL-3R: interleukin-3 receptor; BFU-E: Erythroid blast-forming units; and CFU-E: Erythroid colony- forming units.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_31_12799=[""].join("\n");
var outline_f12_31_12799=null;
